BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: . EASL Clinical Practice Guidelines: Autoimmune hepatitis. Journal of Hepatology 2015;63:971-1004. [DOI: 10.1016/j.jhep.2015.06.030] [Cited by in Crossref: 489] [Cited by in F6Publishing: 395] [Article Influence: 69.9] [Reference Citation Analysis]
Number Citing Articles
1 Sripongpun P, Pongpaibul A, Charatcharoenwitthaya P. Value and risk of percutaneous liver biopsy in patients with cirrhosis and clinical suspicion of autoimmune hepatitis. BMJ Open Gastroenterol 2021;8:e000701. [PMID: 34362759 DOI: 10.1136/bmjgast-2021-000701] [Reference Citation Analysis]
2 Granito A, Muratori P, Muratori L. Acute-on-chronic liver failure: A complex clinical entity in patients with autoimmune hepatitis. J Hepatol 2021;75:1503-5. [PMID: 34228991 DOI: 10.1016/j.jhep.2021.06.035] [Reference Citation Analysis]
3 Stolk MFJ, van den Berg AP, van Erpecum KJ. Maintenance immunosuppressive therapy in autoimmune hepatitis: To stop or not to stop, that is the question. Eur J Intern Med 2021;90:25-6. [PMID: 34024702 DOI: 10.1016/j.ejim.2021.05.005] [Reference Citation Analysis]
4 Schmeltzer PA, Russo MW. Clinical narrative: autoimmune hepatitis. Am J Gastroenterol 2018;113:951-8. [PMID: 29755125 DOI: 10.1038/s41395-018-0058-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
5 Galaski J, Weiler-Normann C, Schakat M, Zachou K, Muratori P, Lampalzer S, Haag F, Schramm C, Lenzi M, Dalekos GN, Lohse AW. Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. J Hepatol 2021;74:312-20. [PMID: 32730794 DOI: 10.1016/j.jhep.2020.07.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gleeson D. Long-Term Outcomes of Autoimmune Hepatitis. Clin Liver Dis (Hoboken) 2019;14:24-8. [PMID: 31391933 DOI: 10.1002/cld.797] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
7 Diestelhorst J, Junge N, Jonigk D, Schlue J, Falk CS, Manns MP, Baumann U, Jaeckel E, Taubert R. Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis. Sci Rep 2018;8:419. [PMID: 29323192 DOI: 10.1038/s41598-017-18818-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
8 Gatselis NK, Vakrakou AG, Zachou K, Androutsakos T, Azariadis K, Hatzis G, Manoussakis MN, Dalekos GN. Decreased serum DNase1-activity in patients with autoimmune liver diseases. Autoimmunity 2017;50:125-32. [DOI: 10.1080/08916934.2017.1279610] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
9 Nasiroglu Imga N, Efe C. Editorial: the role of vitamin D in autoimmune hepatitis. Aliment Pharmacol Ther 2019;49:342-3. [DOI: 10.1111/apt.15075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Biewenga M, Verhelst X, Baven-Pronk M, Putter H, van den Berg A, Colle I, Schouten J, Sermon F, Van Steenkiste C, van Vlierberghe H, van der Meer A, van Hoek B; Dutch Autoimmune Hepatitis Study Group. Aminotransferases During Treatment Predict Long-Term Survival in Patients With Autoimmune Hepatitis Type 1: A Landmark Analysis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00562-0. [PMID: 34022454 DOI: 10.1016/j.cgh.2021.05.024] [Reference Citation Analysis]
11 Buechter M, Manka P, Heinemann FM, Lindemann M, Baba HA, Schlattjan M, Canbay A, Gerken G, Kahraman A. Potential triggering factors of acute liver failure as a first manifestation of autoimmune hepatitis-a single center experience of 52 adult patients. World J Gastroenterol 2018; 24(13): 1410-1418 [PMID: 29632422 DOI: 10.3748/wjg.v24.i13.1410] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
12 Ni XX, Lian M, Wu HM, Li XY, Sheng L, Bao H, Miao Q, Xiao X, Guo CJ, Li H, Ma X, Hua J. Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases. World J Gastroenterol 2021; 27(1): 80-91 [PMID: 33505152 DOI: 10.3748/wjg.v27.i1.80] [Reference Citation Analysis]
13 Kia L, Beattie A, Green RM. Autoimmune hepatitis in patients with human immunodeficiency virus (HIV): Case reports of a rare, but important diagnosis with therapeutic implications. Medicine (Baltimore). 2017;96:e6011. [PMID: 28207511 DOI: 10.1097/md.0000000000006011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
14 Cai W, Ran Y, Li Y, Wang B, Zhou L. Intestinal microbiome and permeability in patients with autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2017;31:669-73. [PMID: 29566910 DOI: 10.1016/j.bpg.2017.09.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
15 Wang T, Men R, Hu M, Fan X, Yang X, Huang X, Ye T, Yang L. Protective effects of Punica granatum (pomegranate) peel extract on concanavalin A-induced autoimmune hepatitis in mice. Biomedicine & Pharmacotherapy 2018;100:213-20. [DOI: 10.1016/j.biopha.2017.12.110] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
16 Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Fracanzani AL, Rosso C, Blanco MJG, Armandi A, Caviglia GP, Zaki MYW, Liguori A, Francione P, Pennisi G, Grieco A, Valenti L, Anstee QM, Bugianesi E. Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2020;115:1289-92. [PMID: 32453041 DOI: 10.14309/ajg.0000000000000676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Balitzer D, Shafizadeh N, Peters MG, Ferrell LD, Alshak N, Kakar S. Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. Mod Pathol. 2017;30:773-783. [PMID: 28106105 DOI: 10.1038/modpathol.2016.267] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
18 Enomoto H, Nishiguchi S. Similarities and Differences in Autoimmune Hepatitis Epidemiology between East and West: Autoimmune Hepatitis in East Asia, Southeast Asia, and South Asia. Inflamm Intest Dis 2017;1:150-8. [PMID: 29922671 DOI: 10.1159/000454879] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
19 Zhu W, Wang L, Zhao X, Wang T, Shi X, Ou X, Wang Y, Wang X, Duan W, Wang Q, Jia J, Ma H. Prolonged interval of total bilirubin decline is an early independent predictive factor of chronic persistent drug‐induced liver injury. Hepatol Res 2020;50:224-32. [DOI: 10.1111/hepr.13435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Joshi D, Gupta N, Samyn M, Deheragoda M, Dobbels F, Heneghan MA. The management of childhood liver diseases in adulthood. Journal of Hepatology 2017;66:631-44. [DOI: 10.1016/j.jhep.2016.11.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
21 Christen U, Hintermann E. Autoantibodies in Autoimmune Hepatitis: Can Epitopes Tell Us about the Etiology of the Disease? Front Immunol. 2018;9:163. [PMID: 29503645 DOI: 10.3389/fimmu.2018.00163] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
22 Di Giorgio A, Vergani D, Mieli-vergani G. Cutting edge issues in juvenile sclerosing cholangitis. Digestive and Liver Disease 2021. [DOI: 10.1016/j.dld.2021.06.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Fontana RJ, Bari K. Acute Liver Failure. In: Schiff ER, Maddrey WC, Reddy KR, editors. Schiff's Diseases of the Liver. Oxford: John Wiley & Sons, Ltd; 2017. pp. 411-31. [DOI: 10.1002/9781119251316.ch17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Jones D, Manns MP, Terracciano L, Torbenson M, Vierling JM. Unmet needs and new models for future trials in autoimmune hepatitis. The Lancet Gastroenterology & Hepatology 2018;3:363-70. [DOI: 10.1016/s2468-1253(18)30043-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
25 Gadour E. Autoimmune Hepatitis: Treatment Options and Management Review. Cureus 2021;13:e15682. [PMID: 34150417 DOI: 10.7759/cureus.15682] [Reference Citation Analysis]
26 Feng TT, Zou T, Wang X, Zhao WF, Qin AL. Clinical significance of changes in the Th17/Treg ratio in autoimmune liver disease. World J Gastroenterol 2017; 23(21): 3832-3838 [PMID: 28638223 DOI: 10.3748/wjg.v23.i21.3832] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
27 Boyd A, Cain O, Chauhan A, Webb GJ. Medical liver biopsy: background, indications, procedure and histopathology. Frontline Gastroenterol 2020;11:40-7. [PMID: 31885839 DOI: 10.1136/flgastro-2018-101139] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
28 Wang Z, Sheng L, Yang Y, Yang F, Xiao X, Hua J, Guo C, Wei Y, Tang R, Miao Q, Zhang J, Li Y, Fang J, Qiu D, Krawitt EL, Bowlus CL, Gershwin ME, Wang Q, Ma X. The Management of Autoimmune Hepatitis Patients with Decompensated Cirrhosis: Real-World Experience and a Comprehensive Review. Clinic Rev Allerg Immunol 2017;52:424-35. [DOI: 10.1007/s12016-016-8583-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
29 Taubert R, Hupa-breier KL, Jaeckel E, Manns MP. Novel therapeutic targets in autoimmune hepatitis. Journal of Autoimmunity 2018;95:34-46. [DOI: 10.1016/j.jaut.2018.10.022] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
30 Wei Y, Li Y, Yan L, Sun C, Miao Q, Wang Q, Xiao X, Lian M, Li B, Chen Y, Zhang J, Li Y, Huang B, Li Y, Cao Q, Fan Z, Chen X, Fang J, Gershwin ME, Tang R, Ma X. Alterations of gut microbiome in autoimmune hepatitis. Gut 2020;69:569-77. [DOI: 10.1136/gutjnl-2018-317836] [Cited by in Crossref: 56] [Cited by in F6Publishing: 61] [Article Influence: 18.7] [Reference Citation Analysis]
31 Czaja AJ. Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. Autoimmunity. 2019;52:144-160. [PMID: 31298041 DOI: 10.1080/08916934.2019.1641200] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
32 Rodrigues EM Filho, Fernandes R, Susin R, Fior B. Immune reconstitution inflammatory syndrome as a cause of autoimmune hepatitis and acute liver failure. Rev Bras Ter Intensiva. 2017;29:382-385. [PMID: 29044307 DOI: 10.5935/0103-507x.20170053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
33 Xue M, Shen Y, Fan X, Shen M, Yang L. Autoimmune Hepatitis with Elevated Serum IgG4 Levels Have a High Prevalence of Cirrhosis at Diagnosis.Can J Gastroenterol Hepatol. 2021;2021:6692511. [PMID: 33489994 DOI: 10.1155/2021/6692511] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Domerecka W, Kowalska-Kępczyńska A, Michalak A, Homa-Mlak I, Mlak R, Cichoż-Lach H, Małecka-Massalska T. Etiopathogenesis and Diagnostic Strategies in Autoimmune Hepatitis. Diagnostics (Basel) 2021;11:1418. [PMID: 34441353 DOI: 10.3390/diagnostics11081418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Liberal R, Gaspar R, Lopes S, Macedo G. Long-term outcome of patients with difficult-to-treat autoimmune hepatitis receiving mycophenolate mofetil. Clin Res Hepatol Gastroenterol 2021;45:101487. [PMID: 32651078 DOI: 10.1016/j.clinre.2020.06.013] [Reference Citation Analysis]
36 Pape S, Schramm C, Gevers TJ. Clinical management of autoimmune hepatitis. United European Gastroenterol J 2019;7:1156-63. [PMID: 31700628 DOI: 10.1177/2050640619872408] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
37 Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments. World J Gastroenterol 2017; 23(33): 6030-6048 [PMID: 28970719 DOI: 10.3748/wjg.v23.i33.6030] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
38 Nunes DRDCMA, Breton MC, Monteiro CSJ, Dos Santos JL. Drug Induced Liver Injury: Perspective of the Adverse Drug Reaction Reports to the Portuguese Pharmacovigilance System from 2010 to 2019. Healthcare (Basel) 2021;9:1630. [PMID: 34946356 DOI: 10.3390/healthcare9121630] [Reference Citation Analysis]
39 Guo L, Zheng L, Hu L, Zhou H, Yu L, Liang W. Transient Elastography (FibroScan) Performs Better Than Non-Invasive Markers in Assessing Liver Fibrosis and Cirrhosis in Autoimmune Hepatitis Patients. Med Sci Monit 2017;23:5106-12. [PMID: 29073121 DOI: 10.12659/msm.907300] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 3.4] [Reference Citation Analysis]
40 McFarlane IM, Bhamra MS, Kreps A, Iqbal S, Al-Ani F, Saladini-Aponte C, Grant C, Singh S, Awwal K, Koci K, Saperstein Y, Arroyo-Mercado FM, Laskar DB, Atluri P. Gastrointestinal Manifestations of Systemic Sclerosis. Rheumatology (Sunnyvale). 2018;8. [PMID: 30057856 DOI: 10.4172/2161-1149.1000235] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
41 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 2021;51:725-49. [PMID: 34228859 DOI: 10.1111/hepr.13678] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
42 Grønbaek L, Vilstrup H, Jepsen P. Pregnancy and birth outcomes in a Danish nationwide cohort of women with autoimmune hepatitis and matched population controls. Aliment Pharmacol Ther 2018;48:655-63. [DOI: 10.1111/apt.14925] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
43 Halliday N, Dyson JK, Thorburn D, Lohse AW, Heneghan MA. Review article: experimental therapies in autoimmune hepatitis. Aliment Pharmacol Ther 2020;52:1134-49. [PMID: 32794592 DOI: 10.1111/apt.16035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Lv T, Li M, Zeng N, Zhang J, Li S, Chen S, Zhang C, Shan S, Duan W, Wang Q, Wu S, You H, Ou X, Ma H, Zhang D, Kong Y, Jia J. Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population. J Gastroenterol Hepatol 2019;34:1676-84. [PMID: 31146297 DOI: 10.1111/jgh.14746] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
45 Muratori P, Carbone M, Stangos G, Perini L, Lalanne C, Ronca V, Cazzagon N, Bianchi G, Lenzi M, Floreani A, Invernizzi P, Muratori L. Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study. Dig Liver Dis 2018;50:698-702. [PMID: 29567415 DOI: 10.1016/j.dld.2018.02.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
46 Choudhary NS, Saigal S, Gautam D, Saraf N, Soin AS. De Novo Autoimmune Hepatitis After Living Donor Liver Transplantation: A Series of 4 Cases. J Clin Exp Hepatol 2018;8:314-7. [PMID: 30302049 DOI: 10.1016/j.jceh.2018.02.004] [Reference Citation Analysis]
47 Löhr JM, Beuers U, Vujasinovic M, Alvaro D, Frøkjær JB, Buttgereit F, Capurso G, Culver EL, de-Madaria E, Della-Torre E, Detlefsen S, Dominguez-Muñoz E, Czubkowski P, Ewald N, Frulloni L, Gubergrits N, Duman DG, Hackert T, Iglesias-Garcia J, Kartalis N, Laghi A, Lammert F, Lindgren F, Okhlobystin A, Oracz G, Parniczky A, Mucelli RMP, Rebours V, Rosendahl J, Schleinitz N, Schneider A, van Bommel EF, Verbeke CS, Vullierme MP, Witt H; UEG guideline working group. European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations. United European Gastroenterol J 2020;8:637-66. [PMID: 32552502 DOI: 10.1177/2050640620934911] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
48 Tanaka A, Notohara K. Immunoglobulin G4 (IgG4)-related autoimmune hepatitis and IgG4-hepatopathy: A histopathological and clinical perspective. Hepatol Res 2021;51:850-9. [PMID: 34165225 DOI: 10.1111/hepr.13683] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Terziroli Beretta-piccoli B, Invernizzi P, Gershwin ME, Mainetti C. Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review. Clinic Rev Allerg Immunol 2017;53:394-412. [DOI: 10.1007/s12016-017-8649-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
50 Deswal S, Srivastava A. Role of Allopurinol in Optimizing Thiopurine Therapy in Patients with Autoimmune Hepatitis: A Review. J Clin Exp Hepatol 2017;7:55-62. [PMID: 28348471 DOI: 10.1016/j.jceh.2017.01.115] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
51 Rahim MN, Liberal R, Miquel R, Heaton ND, Heneghan MA. Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation? Liver Transpl 2019;25:946-59. [PMID: 30900368 DOI: 10.1002/lt.25451] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 11.3] [Reference Citation Analysis]
52 Mieli-vergani G, Vergani D, Baumann U, Czubkowski P, Debray D, Dezsofi A, Fischler B, Gupte G, Hierro L, Indolfi G, Jahnel J, Smets F, Verkade HJ, Hadžić N. Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. Journal of Pediatric Gastroenterology & Nutrition 2018;66:345-60. [DOI: 10.1097/mpg.0000000000001801] [Cited by in Crossref: 100] [Cited by in F6Publishing: 24] [Article Influence: 25.0] [Reference Citation Analysis]
53 Comerford M, Fogel R, Bailey JR, Chilukuri P, Chalasani N, Lammert CS. Leveraging Social Networking Sites for an Autoimmune Hepatitis Genetic Repository: Pilot Study to Evaluate Feasibility. J Med Internet Res 2018;20:e14. [PMID: 29348111 DOI: 10.2196/jmir.7683] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
54 Sebode M, Schulz L, Lohse AW. "Autoimmune(-Like)" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis. Int J Mol Sci 2017;18:E1954. [PMID: 28895915 DOI: 10.3390/ijms18091954] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
55 Wang QX, Yan L, Ma X. Autoimmune Hepatitis in the Asia-Pacific Area. J Clin Transl Hepatol 2018;6:48-56. [PMID: 29577032 DOI: 10.14218/JCTH.2017.00032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
56 Ducazu O, Degroote H, Geerts A, Hoorens A, Schouten J, Van Vlierberghe H, Verhelst X. Diagnostic and prognostic scoring systems for autoimmune hepatitis: a review. Acta Gastroenterol Belg 2021;84:487-95. [PMID: 34599574 DOI: 10.51821/84.3.014] [Reference Citation Analysis]
57 Abe K, Takahashi A, Fujita M, Hayashi M, Okai K, Nozawa Y, Ohira H. Interleukin-33/ST2-Mediated Inflammation Plays a Critical Role in the Pathogenesis and Severity of Type I Autoimmune Hepatitis. Hepatol Commun 2019;3:670-84. [PMID: 31061955 DOI: 10.1002/hep4.1326] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
58 Talbot S, MacLaren V, Lafferty H. Sclerosing cholangitis in a patient treated with nivolumab. BMJ Case Rep 2021;14:e241700. [PMID: 34049893 DOI: 10.1136/bcr-2021-241700] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Anastasiou OE, Dogan-Cavus B, Kucukoglu O, Baba H, Kahraman A, Gerken G, Schramm C, Canbay A. Corticosteroid Therapy Improves the Outcome of Autoimmune Hepatitis-Induced Acute Liver Failure. Digestion 2018;98:104-11. [PMID: 29698940 DOI: 10.1159/000487940] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
60 Mele D, Bossi G, Maggiore G, Oliviero B, Mantovani S, Bonelli B, Mondelli MU, Varchetta S. Altered natural killer cell cytokine profile in type 2 autoimmune hepatitis. Clin Immunol 2018;188:31-7. [PMID: 29233784 DOI: 10.1016/j.clim.2017.12.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
61 Costa-Moreira P, Gaspar R, Pereira P, Lopes S, Canão P, Lopes J, Carneiro F, Macedo G. Role of liver biopsy in the era of clinical prediction scores for "drug-induced liver injury" (DILI): experience of a tertiary referral hospital. Virchows Arch 2020;477:517-25. [PMID: 32377873 DOI: 10.1007/s00428-020-02824-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
62 Biewenga M, Inderson A, Tushuizen ME, Crobach ASLP, van Hoek B. Early Predictors of Short-Term Prognosis in Acute and Acute Severe Autoimmune Hepatitis. Liver Transpl 2020;26:1573-81. [PMID: 32997870 DOI: 10.1002/lt.25906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
63 Gitto S, Campani C, Generini S, Liotta F, Messerini L, Marra F. Statin-induced, immune-mediated injury with simultaneous targeting of skeletal muscle, skin and liver. Intern Emerg Med 2021;16:1719-22. [PMID: 33550534 DOI: 10.1007/s11739-021-02652-9] [Reference Citation Analysis]
64 Zhang W, De D, Mohammed KA, Munigala S, Chen G, Lai JP, Bacon BR. New scoring classification for primary biliary cholangitis-autoimmune hepatitis overlap syndrome. Hepatol Commun 2018;2:245-53. [PMID: 29507900 DOI: 10.1002/hep4.1148] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
65 De Martin E, Coilly A, Chazouillères O, Roux O, Peron JM, Houssel-Debry P, Artru F, Silvain C, Ollivier-Hourmand I, Duvoux C, Heurgue A, Barge S, Ganne-Carrié N, Pageaux GP, Besch C, Bourlière M, Fontaine H, de Ledinghen V, Dumortier J, Conti F, Radenne S, Debette-Gratien M, Goria O, Durand F, Potier P, Di Martino V, Reboux N, Ichai P, Sebagh M, Mathurin P, Agostini H, Samuel D, Duclos-Vallée JC; FILFOIE consortium – France. Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score. J Hepatol 2021;74:1325-34. [PMID: 33503489 DOI: 10.1016/j.jhep.2020.12.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
66 Vergani D, Terziroli Beretta-Piccoli B, Mieli-Vergani G. A reasoned approach to the treatment of autoimmune hepatitis. Dig Liver Dis 2021:S1590-8658(21)00307-8. [PMID: 34162505 DOI: 10.1016/j.dld.2021.05.033] [Reference Citation Analysis]
67 Liu SP, Bian ZH, Zhao ZB, Wang J, Zhang W, Leung PSC, Li L, Lian ZX. Animal Models of Autoimmune Liver Diseases: a Comprehensive Review. Clin Rev Allergy Immunol 2020;58:252-71. [PMID: 32076943 DOI: 10.1007/s12016-020-08778-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
68 Chapman MH, Thorburn D, Hirschfield GM, Webster GGJ, Rushbrook SM, Alexander G, Collier J, Dyson JK, Jones DE, Patanwala I, Thain C, Walmsley M, Pereira SP. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68:1356-1378. [PMID: 31154395 DOI: 10.1136/gutjnl-2018-317993] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 18.3] [Reference Citation Analysis]
69 Wang Y, Li Y, Wang X, Gacesa R, Zhang J, Zhou L, Wang B. Predicting Liver Disease Risk Using a Combination of Common Clinical Markers: A Screening Model from Routine Health Check-Up. Dis Markers 2020;2020:8460883. [PMID: 32566041 DOI: 10.1155/2020/8460883] [Reference Citation Analysis]
70 Arndtz K, Shumbayawonda E, Hodson J, Eddowes PJ, Dennis A, Thomaides-Brears H, Mouchti S, Kelly MD, Banerjee R, Neubauer S, Hirschfield GM. Multiparametric Magnetic Resonance Imaging, Autoimmune Hepatitis, and Prediction of Disease Activity. Hepatol Commun 2021;5:1009-20. [PMID: 34141986 DOI: 10.1002/hep4.1687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 van Gerven NM, de Boer YS, Mulder CJ, van Nieuwkerk CM, Bouma G. Auto immune hepatitis. World J Gastroenterol 2016; 22(19): 4651-4661 [PMID: 27217697 DOI: 10.3748/wjg.v22.i19.4651] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
72 Christen U. Animal models of autoimmune hepatitis. Biochim Biophys Acta Mol Basis Dis 2019;1865:970-81. [PMID: 29857050 DOI: 10.1016/j.bbadis.2018.05.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
73 Zhang C, Wu SS, Dong XQ, Wu Z, Zhao H, Wang GQ. The efficacy and safety of different doses of glucocorticoid for autoimmune hepatitis: A systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e18313. [PMID: 31876706 DOI: 10.1097/MD.0000000000018313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 van den Brand FF, van der Veen KS, Lissenberg-Witte BI, de Boer YS, van Hoek B, Drenth JPH, Verdonk RC, Vrolijk JM, van Nieuwkerk CMJ, Bouma G; Dutch Autoimmune Hepatitis Study Group. Adverse events related to low dose corticosteroids in autoimmune hepatitis. Aliment Pharmacol Ther 2019;50:1120-6. [PMID: 31617229 DOI: 10.1111/apt.15528] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
75 Buitrago-Molina LE, Pietrek J, Noyan F, Schlue J, Manns MP, Wedemeyer H, Hardtke-Wolenski M, Jaeckel E. Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis. J Autoimmun 2021;117:102591. [PMID: 33387980 DOI: 10.1016/j.jaut.2020.102591] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
76 Dyson JK, De Martin E, Dalekos GN, Drenth JP, Herkel J, Hubscher SG, Kelly D, Lenzi M, Milkiewicz P, Oo YH, Heneghan MA, Lohse AW; the IAIHG Consortium. Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop. Aliment Pharmacol Ther 2019;49:528-36. [DOI: 10.1111/apt.15111] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
77 Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017;67:1298-1323. [PMID: 28802875 DOI: 10.1016/j.jhep.2017.07.022] [Cited by in Crossref: 244] [Cited by in F6Publishing: 209] [Article Influence: 48.8] [Reference Citation Analysis]
78 Chalasani S, Mathur K, Shammas N, Orman E, Vuppalanchi R, Lammert C. Hepatic steatosis is highly prevalent but is not correlated with stiffness in autoimmune hepatitis. Medicine (Baltimore) 2020;99:e22805. [PMID: 33080756 DOI: 10.1097/MD.0000000000022805] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 De Maeyer F, Lapauw B, Hoorens A, Geerts A, Van Vlierberghe H, Verhelst X. Secondary Adrenal Insufficiency after Treatment with Budesonide for Autoimmune Hepatitis. Case Rep Gastroenterol 2018;12:597-601. [PMID: 30386198 DOI: 10.1159/000492204] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
80 Webster CRL, Center SA, Cullen JM, Penninck DG, Richter KP, Twedt DC, Watson PJ. ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs. J Vet Intern Med 2019;33:1173-200. [PMID: 30844094 DOI: 10.1111/jvim.15467] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
81 Sucher E, Sucher R, Gradistanac T, Brandacher G, Schneeberger S, Berg T. Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies. J Immunol Res 2019;2019:9437043. [PMID: 31886312 DOI: 10.1155/2019/9437043] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
82 Kemme S, Mack CL. Pediatric Autoimmune Liver Diseases: Autoimmune Hepatitis and Primary Sclerosing Cholangitis. Pediatr Clin North Am 2021;68:1293-307. [PMID: 34736590 DOI: 10.1016/j.pcl.2021.07.006] [Reference Citation Analysis]
83 Fraisse T, Savey L, Hentgen V, Rossi-Semerano L, Koné-Paut I, Grateau G, Georgin-Lavialle S, Ducharme-Bénard S. Non-amyloid liver involvement in familial Mediterranean fever: A systematic literature review. Liver Int 2020;40:1269-77. [PMID: 32196885 DOI: 10.1111/liv.14445] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Sheptulina A, Shirokova E, Nekrasova T, Blum H, Ivashkin V. Platelet count to spleen diameter ratio non-invasively identifies severe fibrosis and cirrhosis in patients with autoimmune hepatitis. J Gastroenterol Hepatol. 2016;31:1956-1962. [PMID: 27059170 DOI: 10.1111/jgh.13407] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
85 Wong LL, Fisher HF, Stocken DD, Rice S, Khanna A, Heneghan MA, Oo YH, Mells G, Kendrick S, Dyson JK, Jones DEJ; UK-AIH Consortium. The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility. Hepatology 2018;68:1487-97. [PMID: 29663477 DOI: 10.1002/hep.30031] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
86 Rocha HC, Vilela EG. Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases. Gastroenterol Hepatol 2021:S0210-5705(21)00153-9. [PMID: 34023469 DOI: 10.1016/j.gastrohep.2021.03.011] [Reference Citation Analysis]
87 Martínez Casas OY, Díaz Ramírez GS, Marín Zuluaga JI, Santos Ó, Muñoz Maya O, Donado Gómez JH, Restrepo Gutiérrez JC. Síndrome de superposición: hepatitis autoinmune y colangitis biliar primaria. Resultados a largo plazo de una cohorte retrospectiva en un hospital universitario. Gastroenterología y Hepatología 2018;41:544-52. [DOI: 10.1016/j.gastrohep.2018.05.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
88 Borssén ÅD, Palmqvist R, Kechagias S, Marschall HU, Bergquist A, Rorsman F, Weiland O, Verbaan H, Nyhlin N, Nilsson E, Werner M. Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis: A cohort study. Medicine (Baltimore) 2017;96:e7708. [PMID: 28834875 DOI: 10.1097/MD.0000000000007708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
89 Hu PF, Xie WF. Corticosteroid therapy in drug-induced liver injury: Pros and cons. J Dig Dis. 2019;20:122-126. [PMID: 30582289 DOI: 10.1111/1751-2980.12697] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
90 Wong G, Yeong T, Lawrence D, Yeoman AD, Verma S, Heneghan MA. Concurrent extrahepatic autoimmunity in autoimmune hepatitis: implications for diagnosis, clinical course and long-term outcomes. Liver Int 2017;37:449-57. [DOI: 10.1111/liv.13236] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
91 Tanaka A. Autoimmune Hepatitis: 2019 Update. Gut Liver 2020;14:430-8. [PMID: 32301319 DOI: 10.5009/gnl19261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
92 Polychronopoulou E, Lygoura V, Gatselis NK, Dalekos GN. Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis. BMJ Case Rep. 2017;2017. [PMID: 28951510 DOI: 10.1136/bcr-2017-220824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
93 Dalekos GN, Azariadis K, Lygoura V, Arvaniti P, Gampeta S, Gatselis NK. Autoimmune hepatitis in patients aged 70 years or older: Disease characteristics, treatment response and outcome. Liver Int 2021;41:1592-9. [PMID: 33896089 DOI: 10.1111/liv.14900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
94 Suarez-Quintero CY, Patarroyo Henao O, Muñoz-Velandia O. Concordance between hepatic biopsy and the APRI index (Ast to Platelet Ratio Index) for the diagnosis of cirrhosis in patients with autoimmune liver disease. Gastroenterol Hepatol 2021;44:465-71. [PMID: 33608136 DOI: 10.1016/j.gastrohep.2020.07.005] [Reference Citation Analysis]
95 Llovet LP, Gratacós-Ginés J, Ortiz O, Rodriguez-Tajes S, Lens S, Reverter E, Ruiz-Ortiz E, Costa J, Viñas O, Forns X, Parés A, Londoño MC. Higher seroprevalence of hepatitis E virus in autoimmune hepatitis: Role of false-positive antibodies. Liver Int 2020;40:558-64. [PMID: 31863722 DOI: 10.1111/liv.14332] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
96 Schmidt T, Schmidt C, Strahl A, Mussawy H, Rolvien T, Jandl NM, Casar C, Oheim R, Schinke T, Lohse AW, Amling M, Schramm C, Barvencik F. A System to Determine Risk of Osteoporosis in Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2020;18:226-233.e3. [PMID: 31163277 DOI: 10.1016/j.cgh.2019.05.043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
97 Silva MJ, Dellavance A, Baldo DC, Rodrigues SH, Grecco M, Prado MS, Agustinelli R, Andrade LEC. Interkit Reproducibility of the Indirect Immunofluorescence Assay on HEp-2 Cells Depends on the Immunofluorescence Reactivity Intensity and Pattern. Front Immunol 2022;12:798322. [DOI: 10.3389/fimmu.2021.798322] [Reference Citation Analysis]
98 Rigopoulou EI, Gyftaki S, Arvaniti P, Tsimourtou V, Koukoulis GK, Hadjigeorgiou G, Dalekos GN. Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment. Clin Res Hepatol Gastroenterol 2019;43:e25-32. [PMID: 30594597 DOI: 10.1016/j.clinre.2018.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
99 Zayed N, Darweesh SK, Mousa S, Atef M, Ramzy E, Yosry A. Liver stiffness measurement by acoustic radiation forced impulse and transient elastography in patients with intrahepatic cholestasis. Eur J Gastroenterol Hepatol. 2019;31:520-527. [PMID: 30807445 DOI: 10.1097/meg.0000000000001327] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
100 de Boer YS, Liberal R, Vergani D, Mieli-Vergani G. Real-world management of juvenile autoimmune liver disease. United European Gastroenterol J 2018;6:1032-8. [PMID: 30228891 DOI: 10.1177/2050640618768922] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
101 Efe C, Simşek C, Batıbay E, Calışkan AR, Wahlin S. Feasibility of telehealth in the management of autoimmune hepatitis before and during the COVID-19 pandemic. Expert Rev Gastroenterol Hepatol 2020;14:1215-9. [PMID: 32909852 DOI: 10.1080/17474124.2020.1822734] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
102 Taneja S, Kumar P, Mitra S, Duseja A, Minz R, Das A, Dhiman RK, Chawla Y. Acute Exacerbation to Autoimmune Hepatitis Mimicking Acute Viral Hepatitis-A Case Series and Review of Literature. J Clin Exp Hepatol 2018;8:98-103. [PMID: 29743801 DOI: 10.1016/j.jceh.2017.08.005] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
103 Di Giorgio A, D'Adda A, Marseglia A, Sonzogni A, Licini L, Nicastro E, D'Antiga L. Biliary features in liver histology of children with autoimmune liver disease. Hepatol Int 2019;13:510-8. [PMID: 31069759 DOI: 10.1007/s12072-019-09948-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
104 Ngu JH, Gearry RB, Stedman CAM. Autoimmune Hepatitis in the East and the West. Inflamm Intest Dis 2017;1:147-9. [PMID: 29922670 DOI: 10.1159/000455177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
105 Zachou K, Gatselis NK, Arvaniti P, Gabeta S, Rigopoulou EI, Koukoulis GK, Dalekos GN. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. Aliment Pharmacol Ther. 2016;43:1035-1047. [PMID: 26991238 DOI: 10.1111/apt.13584] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
106 Fuchs S, Bayer M, Taubert R, Manns MP, Pfeilschifter JM, Christen U, Hintermann E. Effects of adenovirus-induced hepatocyte damage on chronic bile duct inflammation in a sclerosing cholangitis mouse model. Liver Int 2019;39:2330-40. [PMID: 31225929 DOI: 10.1111/liv.14183] [Reference Citation Analysis]
107 Lal D, Thakur M, Bihari C. Serum Leptin Serves as an Inflammatory Activity Marker and Predicts Steroid Response in Autoimmune Hepatitis. J Clin Exp Hepatol 2020;10:574-80. [PMID: 33311894 DOI: 10.1016/j.jceh.2020.04.014] [Reference Citation Analysis]
108 Somroo GB, Rai AA, Luck NH, Abbas Z. Clinical presentation of autoimmune hepatitis in Pakistani children. Pan Afr Med J 2018;30:117. [PMID: 30364457 DOI: 10.11604/pamj.2018.30.117.12692] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
109 Sebode M, Hartl J, Vergani D, Lohse AW; International Autoimmune Hepatitis Group (IAIHG). Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda. Liver Int 2018;38:15-22. [PMID: 28432836 DOI: 10.1111/liv.13458] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 7.6] [Reference Citation Analysis]
110 Katsumi T, Ueno Y. Epidemiology and surveillance of autoimmune hepatitis in Asia. Liver Int 2022. [PMID: 34990076 DOI: 10.1111/liv.15155] [Reference Citation Analysis]
111 Matarazzo L, Nastasio S, Sciveres M, Maggiore G. Pregnancy outcome in women with childhood onset autoimmune hepatitis and autoimmune sclerosing cholangitis on long-term immunosuppressive treatment. Eur J Obstet Gynecol Reprod Biol 2021;268:7-11. [PMID: 34788721 DOI: 10.1016/j.ejogrb.2021.10.030] [Reference Citation Analysis]
112 Christen U, Hintermann E. Pathogens and autoimmune hepatitis. Clin Exp Immunol. 2019;195:35-51. [PMID: 30113082 DOI: 10.1111/cei.13203] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
113 Enc F, Ulasoglu C. A case of autoimmune hepatitis following pegylated interferon treatment of chronic hepatitis delta. North Clin Istanb 2020;7:407-10. [PMID: 33043269 DOI: 10.14744/nci.2019.47701] [Reference Citation Analysis]
114 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145-172. [PMID: 28427765 DOI: 10.1016/j.jhep.2017.03.022] [Cited by in Crossref: 409] [Cited by in F6Publishing: 326] [Article Influence: 81.8] [Reference Citation Analysis]
115 Pape S, Gevers TJ, Belias M, Mustafajev IF, Vrolijk JM, van Hoek B, Bouma G, van Nieuwkerk CM, Hartl J, Schramm C, Lohse AW, Taubert R, Jaeckel E, Manns MP, Papp M, Stickel F, Heneghan MA, Drenth JP. Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology 2019;17:2068-2075.e2. [DOI: 10.1016/j.cgh.2018.12.035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
116 Liberal R, Mieli-Vergani G, Vergani D. Contemporary issues and future directions in autoimmune hepatitis. Expert Rev Gastroenterol Hepatol 2016;10:1163-74. [PMID: 27215278 DOI: 10.1080/17474124.2016.1193004] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
117 Schulz L, Sebode M, Weidemann SA, Lohse AW. Variant syndromes of primary biliary cholangitis. Best Practice & Research Clinical Gastroenterology 2018;34-35:55-61. [DOI: 10.1016/j.bpg.2018.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
118 Schmidt C, Stürznickel J, Strahl A, Oheim R, Weiler-Normann C, Sebode M, Barvencik F, Lohse AW, Schinke T, Amling M, Schramm C, Rolvien T. Bone microarchitecture in patients with autoimmune hepatitis. J Bone Miner Res 2021;36:1316-25. [PMID: 33724539 DOI: 10.1002/jbmr.4289] [Reference Citation Analysis]
119 Prokopič M, Beuers U. Management of primary sclerosing cholangitis and its complications: an algorithmic approach. Hepatol Int 2021;15:6-20. [PMID: 33377990 DOI: 10.1007/s12072-020-10118-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
120 Goertz RS, GaBmann L, Strobel D, Wildner D, Schellhaas B, Neurath MF, Pfeifer L. Acoustic Radiation Force Impulse (ARFI) Elastography in Autoimmune and Cholestatic Liver Diseases. Ann Hepatol 2019;18:23-9. [PMID: 31113596 DOI: 10.5604/01.3001.0012.7858] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
121 Yassin S, De Lacy R, Pillay K, Goddard E. Characteristics and Outcomes of Autoimmune Hepatitis from a Tertiary Paediatric Centre, Cape Town, South Africa. J Trop Pediatr 2020;66:448-57. [PMID: 31943108 DOI: 10.1093/tropej/fmz088] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
122 Cropley A, Weltman M. The use of immunosuppression in autoimmune hepatitis: A current literature review. Clin Mol Hepatol 2017;23:22-6. [PMID: 28288505 DOI: 10.3350/cmh.2016.0089] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
123 Santos BC, Guedes LR, Faria LC, Couto CA. Wilson's disease presentation resembling autoimmune hepatitis. BMJ Case Rep 2019;12:e230721. [PMID: 31653624 DOI: 10.1136/bcr-2019-230721] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
124 Dumortier J, Besch C, Moga L, Coilly A, Conti F, Corpechot C, Bello AD, Faitot F, Francoz C, Hilleret MN, Houssel-Debry P, Jezequel C, Lavayssière L, Neau-Cransac M, Erard-Poinsot D, de Lédinghen V, Bourlière M, Bureau C, Ganne-Carrié N. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP IN LIVER TRANSPLANTATION. Clin Res Hepatol Gastroenterol 2021;:101774. [PMID: 34332131 DOI: 10.1016/j.clinre.2021.101774] [Reference Citation Analysis]
125 Liberal R, Krawitt EL, Vierling JM, Manns MP, Mieli-Vergani G, Vergani D. Cutting edge issues in autoimmune hepatitis. J Autoimmun. 2016;75:6-19. [PMID: 27502148 DOI: 10.1016/j.jaut.2016.07.005] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 9.7] [Reference Citation Analysis]
126 Li SS, Niu M, Jing J, Huang Y, Zhang ZT, Chen SS, Shi GZ, He X, Zhang HZ, Xiao XH, Zou ZS, Yu YC, Wang JB. Metabolomic Signatures of Autoimmune Hepatitis in the Development of Cirrhosis. Front Med (Lausanne) 2021;8:644376. [PMID: 33777984 DOI: 10.3389/fmed.2021.644376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Nastasio S, Sciveres M, Matarazzo L, Malaventura C, Cirillo F, Riva S, Maggiore G. Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine. Digestive and Liver Disease 2019;51:712-8. [DOI: 10.1016/j.dld.2018.10.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
128 Ronca V, Bozward AG, Oo YH. Use of immunosuppression in non-transplant hepatology. Best Pract Res Clin Gastroenterol 2021;54-55:101760. [PMID: 34874849 DOI: 10.1016/j.bpg.2021.101760] [Reference Citation Analysis]
129 Chen RL, Wang QX, Ma X. Precision medicine for autoimmune hepatitis. J Dig Dis 2019;20:331-7. [PMID: 31099976 DOI: 10.1111/1751-2980.12786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
130 Miehlke S, Acosta MB, Bouma G, Carpio D, Magro F, Moreels T, Probert C. Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician: Optimising therapy with budesonide. Journal of Gastroenterology and Hepatology 2018;33:1574-81. [DOI: 10.1111/jgh.14151] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
131 Azariadis K, Gatselis NK, Koukoulis GK, Dalekos GN. Glycogenic hepatopathy as a cause of severe deranged liver enzymes in a young patient with type 1 diabetes mellitus. BMJ Case Rep 2019;12:e228524. [PMID: 30898943 DOI: 10.1136/bcr-2018-228524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
132 Ortega-Alonso A, Andrade RJ. Chronic liver injury induced by drugs and toxins. J Dig Dis 2018;19:514-21. [PMID: 29808546 DOI: 10.1111/1751-2980.12612] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
133 Araki T, Arinaga-hino T, Koga H, Akiba J, Ide T, Okabe Y, Kuwahara R, Amano K, Yasumoto M, Kawaguchi T, Sano T, Kondou R, Kurata S, Mitsuyama K, Torimura T. Marked accumulation of fluorodeoxyglucose and inflammatory cells expressing glucose transporter-3 in immunoglobulin G4-related autoimmune hepatitis: Expression of FDG and Glut-3 in IgG4-related AIH. Hepatol Res 2018;48:937-44. [DOI: 10.1111/hepr.13188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
134 Keller S, Aigner A, Zenouzi R, Kim AC, Meijer A, Weidemann SA, Krech T, Lohse AW, Adam G, Schramm C, Yamamura J. Association of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis. PLoS One. 2018;13:e0193929. [PMID: 29513767 DOI: 10.1371/journal.pone.0193929] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
135 de Boer YS, Gerussi A, van den Brand FF, Wong GW, Halliday N, Liberal R, Drenth JPH, Thorburn D, Bouma G, Heneghan MA; Dutch Autoimmune Hepatitis Study Group. Association Between Black Race and Presentation and Liver-Related Outcomes of Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2019;17:1616-1624.e2. [PMID: 30471454 DOI: 10.1016/j.cgh.2018.11.028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
136 Arvaniti P, Giannoulis G, Gabeta S, Zachou K, Koukoulis GK, Dalekos GN. Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis. JHEP Rep 2020;2:100123. [PMID: 32671332 DOI: 10.1016/j.jhepr.2020.100123] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
137 Ivashkin VT, Baranovsky AY, Raikhelson KL, Palgova LK, Maevskaya MV, Kondrashina EA, Marchenko NV, Nekrasova TP, Nikitin IG. Drug-Induced Liver Injuries (Clinical Guidelines for Physicians). Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2019;29:101-31. [DOI: 10.22416/1382-4376-2019-29-1-101-131] [Cited by in Crossref: 18] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
138 El‐serag HB. Epidemiology of Hepatocellular Carcinoma. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 758-72. [DOI: 10.1002/9781119436812.ch59] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
139 Takahashi A, Ohira H, Abe K, Zeniya M, Abe M, Arinaga-Hino T, Torimura T, Yoshizawa K, Takaki A, Kang JH, Suzuki Y, Nakamoto N, Inui A, Tanaka A, Takikawa H. Increasing incidence of acute autoimmune hepatitis: a nationwide survey in Japan. Sci Rep 2020;10:14250. [PMID: 32859968 DOI: 10.1038/s41598-020-71296-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
140 Zoboli F, Ripamonti D, Benatti SV, Comi L, Rizzi M. Autoimmune hepatitis and HIV infection: two case reports and review of the literature. AIDS. 2017;31:2172-2175. [PMID: 28906281 DOI: 10.1097/qad.0000000000001608] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
141 Dalekos GN, Gatselis NK. Variant and Specific Forms of Autoimmune Cholestatic Liver Diseases. Arch Immunol Ther Exp (Warsz) 2019;67:197-211. [PMID: 31165900 DOI: 10.1007/s00005-019-00550-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
142 Granito A, Muratori L, Tovoli F, Muratori P. Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis. Nat Rev Rheumatol 2021;17:244. [PMID: 33462415 DOI: 10.1038/s41584-021-00573-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
143 Di Giorgio A, Tulone A, Nicastro E, Norsa L, Sonzogni A, D'Antiga L. Use of oral vancomycin in children with autoimmune liver disease: A single centre experience. World J Hepatol 2021; 13(12): 2113-2127 [DOI: 10.4254/wjh.v13.i12.2113] [Reference Citation Analysis]
144 Ghannam M, Mansour S, Nabulsi A, Abdoh Q. Anticonvulsant hypersensitivity syndrome after phenytoin administration in an adolescent patient: a case report and review of literature. Clin Mol Allergy 2017;15:14. [PMID: 28638280 DOI: 10.1186/s12948-017-0069-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
145 Wang Y, Guo X, Jiao G, Luo L, Zhou L, Zhang J, Wang B. Splenectomy Promotes Macrophage Polarization in a Mouse Model of Concanavalin A- (ConA-) Induced Liver Fibrosis. Biomed Res Int 2019;2019:5756189. [PMID: 30723740 DOI: 10.1155/2019/5756189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
146 Löve A, Björnsdottir TB, Olafsson S, Björnsson ES. Low prevalence of hepatitis E in Iceland: a seroepidemiological study. Scand J Gastroenterol 2018;53:293-6. [PMID: 29310474 DOI: 10.1080/00365521.2017.1420218] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
147 Zachou K, Arvaniti P, Lyberopoulou A, Dalekos GN. Impact of genetic and environmental factors on autoimmune hepatitis. J Transl Autoimmun 2021;4:100125. [PMID: 34622188 DOI: 10.1016/j.jtauto.2021.100125] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Janmohamed A, Hirschfield GM. Autoimmune hepatitis and complexities in management. Frontline Gastroenterol 2019;10:77-87. [PMID: 30651962 DOI: 10.1136/flgastro-2018-101015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
149 Cristoferi L, Nardi A, Invernizzi P, Mells G, Carbone M. Individualizing Care: Management Beyond Medical Therapy. Surg Oncol Clin N Am 2020;29:87-103. [PMID: 31757316 DOI: 10.1016/j.soc.2019.08.007] [Reference Citation Analysis]
150 Thomaides-Brears HB, Lepe R, Banerjee R, Duncker C. Multiparametric MR mapping in clinical decision-making for diffuse liver disease. Abdom Radiol (NY). 2020;45:3507-3522. [PMID: 32761254 DOI: 10.1007/s00261-020-02684-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
151 Heinemann M, Adam R, Berenguer M, Mirza D, Malek-Hosseini SA, O'Grady JG, Lodge P, Pratschke J, Boudjema K, Paul A, Zieniewicz K, Fronek J, Weiss KH, Karam V, Duvoux C, Lohse A, Schramm C; all the other contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA). Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant Registry. Liver Transpl 2020;26:866-77. [PMID: 32112516 DOI: 10.1002/lt.25739] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
152 Olsen K, Hodson J, Ronca V, Bozward AG, Hayden J, Wootton G, Armstrong M, Adams DH, El-Sherif O, Ferguson J, Knox E, Johnston T, Thompson F, Oo YH. Type 2 Autoimmune Hepatitis and Nonadherence to Medication Correlate With Premature Birth and Risk of Postpartum Flare. Hepatol Commun 2021;5:1252-64. [PMID: 34278173 DOI: 10.1002/hep4.1714] [Reference Citation Analysis]
153 Haridy J, Nicoll A, Sood S. Methotrexate Therapy for Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2018;16:288-9. [PMID: 28711687 DOI: 10.1016/j.cgh.2017.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
154 Putra J, Toor A, Suriawinata AA. The utility of repeat liver biopsy in autoimmune hepatitis: a series of 20 consecutive cases. Pathology. 2016;48:449-453. [PMID: 27306577 DOI: 10.1016/j.pathol.2016.05.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
155 Kang MK, Park JG, Choi JH. Anti-nuclear antibody-negative immunoglobulin G4-associated autoimmune hepatitis mimicking lymphoproliferative disorders. Yeungnam Univ J Med 2020;37:136-40. [PMID: 32204580 DOI: 10.12701/yujm.2020.00066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
156 Freedman BL, Danford CJ, Patwardhan V, Bonder A. Treatment of Overlap Syndromes in Autoimmune Liver Disease: A Systematic Review and Meta-Analysis. J Clin Med 2020;9:E1449. [PMID: 32414025 DOI: 10.3390/jcm9051449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
157 Yuan X, Duan SZ, Cao J, Gao N, Xu J, Zhang L. Noninvasive inflammatory markers for assessing liver fibrosis stage in autoimmune hepatitis patients. Eur J Gastroenterol Hepatol 2019;31:1467-74. [PMID: 31107735 DOI: 10.1097/MEG.0000000000001437] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
158 Covelli C, Sacchi D, Sarcognato S, Cazzagon N, Grillo F, Baciorri F, Fanni D, Cacciatore M, Maffeis V, Guido M. Pathology of autoimmune hepatitis. Pathologica 2021;113:185-93. [PMID: 34294936 DOI: 10.32074/1591-951X-241] [Reference Citation Analysis]
159 Vollmer O, Felten R, Mertz P, Lebrun-vignes B, Salem J, Arnaud L. Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: An analysis of 389 cases in VigiBase. Autoimmunity Reviews 2020;19:102460. [DOI: 10.1016/j.autrev.2020.102460] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
160 van den Brand FF, Snijders RJALM, de Boer YS, Verwer BJ, van Nieuwkerk CMJ, Bloemena E, Kuiken SD, Drenth JPH, Bouma G. Drug withdrawal in patients with autoimmune hepatitis in long-term histological remission: A prospective observational study. Eur J Intern Med 2021;90:30-6. [PMID: 33865679 DOI: 10.1016/j.ejim.2021.03.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 European Association for the Study of the Liver;  Clinical Practice Guideline Panel: Chair;  Panel members;  EASL Governing Board representative. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70:1222-1261. [PMID: 30926241 DOI: 10.1016/j.jhep.2019.02.014] [Cited by in Crossref: 198] [Cited by in F6Publishing: 155] [Article Influence: 66.0] [Reference Citation Analysis]
162 Khanam A, Kottilil S. Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management. Front Med (Lausanne) 2021;8:752875. [PMID: 34820395 DOI: 10.3389/fmed.2021.752875] [Reference Citation Analysis]
163 Biewenga M, Farina Sarasqueta A, Tushuizen ME, de Jonge-Muller ESM, van Hoek B, Trouw LA. The role of complement activation in autoimmune liver disease. Autoimmun Rev 2020;19:102534. [PMID: 32234403 DOI: 10.1016/j.autrev.2020.102534] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
164 Peiseler M, Liebscher T, Sebode M, Zenouzi R, Hartl J, Ehlken H, Pannicke N, Weiler-Normann C, Lohse AW, Schramm C. Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol. 2018;16:260-267.e1. [PMID: 28126427 DOI: 10.1016/j.cgh.2016.12.040] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 6.4] [Reference Citation Analysis]
165 Bovensiepen CS, Schakat M, Sebode M, Zenouzi R, Hartl J, Peiseler M, Li J, Henze L, Woestemeier A, Schramm C, Lohse AW, Herkel J, Weiler-Normann C. TNF-Producing Th1 Cells Are Selectively Expanded in Liver Infiltrates of Patients with Autoimmune Hepatitis. J Immunol 2019;203:3148-56. [PMID: 31685647 DOI: 10.4049/jimmunol.1900124] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
166 Dong Y, Potthoff A, Klinger C, Barreiros AP, Pietrawski D, Dietrich CF. Ultrasound findings in autoimmune hepatitis. World J Gastroenterol 2018; 24(15): 1583-1590 [PMID: 29686465 DOI: 10.3748/wjg.v24.i15.1583] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
167 Milkiewicz P, Krawczyk M, Wunsch E, Ponsioen C, Hirschfield GM, Hubscher SG. Primary Sclerosing Cholangitis With Features of Autoimmune Hepatitis: Exploring the Global Variation in Management. Hepatol Commun 2020;4:399-408. [PMID: 32140656 DOI: 10.1002/hep4.1467] [Reference Citation Analysis]
168 Puustinen L, Boyd S, Mustonen H, Arkkila P, Arola J, Färkkilä M. Prognostic value of clinical variables and liver histology for development of fibrosis and cirrhosis in autoimmune hepatitis. Scandinavian Journal of Gastroenterology 2017;52:321-7. [DOI: 10.1080/00365521.2016.1253768] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
169 Buitrago-Molina LE, Dywicki J, Noyan F, Schepergerdes L, Pietrek J, Lieber M, Schlue J, Manns MP, Wedemeyer H, Jaeckel E, Hardtke-Wolenski M. Anti-CD20 Therapy Alters the Protein Signature in Experimental Murine AIH, but Not Exclusively towards Regeneration. Cells 2021;10:1471. [PMID: 34208308 DOI: 10.3390/cells10061471] [Reference Citation Analysis]
170 Moriya K, Nishimura N, Namisaki T, Takaya H, Sawada Y, Kawaratani H, Kaji K, Shimozato N, Sato S, Furukawa M, Douhara A, Akahane T, Mitoro A, Yamao J, Yoshiji H. Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis. J Clin Med 2021;10:2465. [PMID: 34199421 DOI: 10.3390/jcm10112465] [Reference Citation Analysis]
171 Jones DEJ, Sturm E, Lohse AW. Access to care in rare liver diseases: New challenges and new opportunities. J Hepatol 2018;68:577-85. [PMID: 29113911 DOI: 10.1016/j.jhep.2017.11.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
172 Lohse AW, Sebode M, Jørgensen MH, Ytting H, Karlsen TH, Kelly D, Manns MP, Vesterhus M. Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. Journal of Hepatology 2020;73:1496-506. [DOI: 10.1016/j.jhep.2020.07.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
173 Mitra S, Minz RW. Autoantibodies in Autoimmune Liver Diseases-Methods of Detection and Interpretation: An Update for the Reporting Pathologist. Int J Surg Pathol 2016;24:576-85. [PMID: 27388199 DOI: 10.1177/1066896916657643] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
174 Czaja AJ. Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management. Expert Rev Gastroenterol Hepatol 2018;12:547-64. [PMID: 29540068 DOI: 10.1080/17474124.2018.1453356] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
175 Kumar N, Poddar U, Yadav R, Lal H, Pani K, Yachha SK, Srivastava A, Pandey R. Autoimmune Sclerosing Cholangitis in Children: A Prospective Case-Control Study. Pediatr Gastroenterol Hepatol Nutr 2021;24:154-63. [PMID: 33833971 DOI: 10.5223/pghn.2021.24.2.154] [Reference Citation Analysis]
176 Durazzo M, Ponzo E, Bonetto S, Fagoonee S, Pellicano R. Liver diseases in the elderly. Minerva Med 2019;110. [DOI: 10.23736/s0026-4806.18.05858-5] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
177 Noreña I, Morantes-Caballero JA, Garcés A, Gómez BJ, Rodríguez G, Saavedra C, Otero W. Autoimmune hepatitis in human immunodeficiency virus infection: Case report and literature review. World J Clin Infect Dis 2017; 7(4): 50-57 [DOI: 10.5495/wjcid.v7.i4.50] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
178 Eder M, Omic H, Gorges J, Badt F, Kikic Z, Saemann MD, Tong A, Bauer D, Semmler G, Reiberger T, Lagler H, Scheiner B. Influenza vaccination uptake and factors influencing vaccination decision among patients with chronic kidney or liver disease. PLoS One 2021;16:e0249785. [PMID: 33848305 DOI: 10.1371/journal.pone.0249785] [Reference Citation Analysis]
179 Sharma S, Agarwal S, Kaushal K, Anand A, Gunjan D, Yadav R, Saraya A. Presence and type of decompensation affects outcomes in autoimmune hepatitis upon treatment with corticosteroids. JGH Open 2021;5:81-90. [PMID: 33490617 DOI: 10.1002/jgh3.12451] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Janowski K, Shumbayawonda E, Cheng L, Langford C, Dennis A, Kelly M, Pronicki M, Grajkowska W, Wozniak M, Pawliszak P, Chełstowska S, Jurkiewicz E, Banerjee R, Socha P. Quantitative multiparametric MRI as a non-invasive stratification tool in children and adolescents with autoimmune liver disease. Sci Rep 2021;11:15261. [PMID: 34315985 DOI: 10.1038/s41598-021-94754-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 Muratori P, Efe C, Muratori L, Ozaslan E, Schiano T, Yoshida EM, Heurgué-berlot A, Lalanne C, Lenzi M, Wahlin S. Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis: a multicentre study. European Journal of Gastroenterology & Hepatology 2017;29:777-80. [DOI: 10.1097/meg.0000000000000870] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
182 Stephens C, Lucena MI, Andrade RJ. Genetic risk factors in the development of idiosyncratic drug-induced liver injury. Expert Opinion on Drug Metabolism & Toxicology 2021;17:153-69. [DOI: 10.1080/17425255.2021.1854726] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
183 . UEG Week 2016 Poster Presentations. United European Gastroenterology Journal 2016;4:A157-720. [DOI: 10.1177/2050640616663689] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
184 Collins-Yoder A. Gastrointestinal Manifestations of Autoimmune Diseases Requiring Critical Care. Crit Care Nurs Clin North Am 2018;30:1-12. [PMID: 29413204 DOI: 10.1016/j.cnc.2017.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
185 Chaiteerakij R, Sanpawat A, Avihingsanon A, Treeprasertsuk S. Autoimmune hepatitis in human immunodeficiency virus-infected patients: A case series and review of the literature. World J Gastroenterol 2019; 25(35): 5388-5402 [PMID: 31558881 DOI: 10.3748/wjg.v25.i35.5388] [Cited by in CrossRef: 2] [Article Influence: 0.7] [Reference Citation Analysis]
186 Legué C, Legros L, Kammerer-Jacquet S, Jézequel C, Houssel-Debry P, Uguen T, Le Lan C, Guillygomarc'h A, Moirand R, Turlin B, Guyader D, Bardou-Jacquet E. Safety and Efficacy of 6-thioguanine as a Second-line Treatment for Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2018;16:290-1. [PMID: 28782666 DOI: 10.1016/j.cgh.2017.07.032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
187 Wehrman A, Waisbourd-zinman O, Shah A, Hilmara D, Lin H, Rand EB. Steroid Free Treatment of Autoimmune Hepatitis in Selected Children. The Journal of Pediatrics 2019;207:244-7. [DOI: 10.1016/j.jpeds.2018.12.070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Afaa TJ, Amegan-Aho KH, Dono MT, Odei E, Awuku YA. Clinical characteristics of paediatric autoimmune hepatitis at a referral hospital in Sub Saharan Africa. PLoS One 2020;15:e0239964. [PMID: 33362271 DOI: 10.1371/journal.pone.0239964] [Reference Citation Analysis]
189 Ofori E, Ramai D, Ona MA, Reddy M. Autoimmune hepatitis in the setting of human immunodeficiency virus infection: A case series. World J Hepatol 2017; 9(36): 1367-1371 [PMID: 29359021 DOI: 10.4254/wjh.v9.i36.1367] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
190 Gaspar R, Branco CC, Macedo G. Liver manifestations and complications in inflammatory bowel disease: A review. World J Hepatol 2021; 13(12): 1956-1967 [DOI: 10.4254/wjh.v13.i12.1956] [Reference Citation Analysis]
191 Janik MK, Smyk W, Kruk B, Szczepankiewicz B, Górnicka B, Lebiedzińska-arciszewska M, Potes Y, Simões ICM, Weber SN, Lammert F, Więckowski MR, Milkiewicz P, Krawczyk M. MARC1 p.A165T variant is associated with decreased markers of liver injury and enhanced antioxidant capacity in autoimmune hepatitis. Sci Rep 2021;11. [DOI: 10.1038/s41598-021-03521-3] [Reference Citation Analysis]
192 Nayagam JS, Heneghan MA, Samyn M, Joshi D. Epstein-Barr virus status and immunosuppression use in paediatric autoimmune liver disease. Aliment Pharmacol Ther 2021. [PMID: 34796537 DOI: 10.1111/apt.16708] [Reference Citation Analysis]
193 Franceschini T, Vasuri F, Muratori P, Muratori L, Guido M, Lenzi M, D'Errico A. A practical histological approach to the diagnosis of autoimmune hepatitis: experience of an Italian tertiary referral center. Virchows Arch 2021. [PMID: 34189631 DOI: 10.1007/s00428-021-03122-5] [Reference Citation Analysis]
194 Aizawa Y, Hokari A. Autoimmune hepatitis: current challenges and future prospects. Clin Exp Gastroenterol. 2017;10:9-18. [PMID: 28176894 DOI: 10.2147/ceg.s101440] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
195 Cargill T, Culver EL. The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases. Front Immunol 2021;12:661196. [PMID: 33936097 DOI: 10.3389/fimmu.2021.661196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Sokollik C, Mclin VA, Vergani D, Terziroli Beretta-piccoli B, Mieli-vergani G. Juvenile autoimmune hepatitis: A comprehensive review. Journal of Autoimmunity 2018;95:69-76. [DOI: 10.1016/j.jaut.2018.10.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
197 Choi J, Choi GH, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS, Kim KM. Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country. Liver Int 2019;39:985-94. [PMID: 30821090 DOI: 10.1111/liv.14082] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
198 Gustot T, Stadlbauer V, Laleman W, Alessandria C, Thursz M. Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. J Hepatol 2021;75 Suppl 1:S36-48. [PMID: 34039491 DOI: 10.1016/j.jhep.2020.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
199 Sebode M, Weiler-Normann C, Liwinski T, Schramm C. Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance. Front Immunol. 2018;9:609. [PMID: 29636752 DOI: 10.3389/fimmu.2018.00609] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
200 Prati D, Colli A. When a liver biopsy is 'normal'…. Liver Int 2016;36:21-3. [PMID: 26386367 DOI: 10.1111/liv.12967] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
201 Fan X, Yin D, Men R, Xu H, Yang L. NUDT15 Polymorphism Confer Increased Susceptibility to Thiopurine-Induced Leukopenia in Patients With Autoimmune Hepatitis and Related Cirrhosis. Front Pharmacol 2019;10:346. [PMID: 31024313 DOI: 10.3389/fphar.2019.00346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
202 Dyson JK, Wong LL, Bigirumurame T, Hirschfield GM, Kendrick S, Oo YH, Lohse AW, Heneghan MA, Jones DEJ; UK-AIH Consortium. Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. Aliment Pharmacol Ther 2018;48:951-60. [PMID: 30226274 DOI: 10.1111/apt.14968] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
203 Bombaci M, Pesce E, Torri A, Carpi D, Crosti M, Lanzafame M, Cordiglieri C, Sinisi A, Moro M, Bernuzzi F, Gerussi A, Geginat J, Muratori L, Terracciano LM, Invernizzi P, Abrignani S, Grifantini R. Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms. Liver Int 2019;39:2124-35. [PMID: 31033124 DOI: 10.1111/liv.14128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
204 Larrey D, Meunier L, Ursic-Bedoya J. Liver Biopsy in Chronic Liver Diseases: Is There a Favorable Benefit: Risk Balance? Ann Hepatol. 2017;16:487-489. [PMID: 28612749 DOI: 10.5604/01.3001.0010.0272] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
205 Poizot-Martin I, Rosenthal E, Gilbert C, Cano CE, Simon A, Lascoux-Combe C, Alric L, Gervais A, Neau D, Esterle L, Salmon D, Sogni P, Wittkop L; ANRS CO13 HEPAVIH Study Group. Nadir CD4 Is Negatively Associated With Antinuclear Antibody Detection in HCV/HIV-Coinfected Patients. J Acquir Immune Defic Syndr 2019;80:461-6. [PMID: 30570526 DOI: 10.1097/QAI.0000000000001940] [Reference Citation Analysis]
206 Choi JK, Ahn S, Cho JY, Choi Y, Han HS, Jang BO, Choi GH, Jang ES, Kim JW, Jeong SH. A case of acute liver failure due to hepatitis E virus, liver transplantation, and development of de novo autoimmune hepatitis. Transpl Infect Dis 2020;22:e13287. [PMID: 32279435 DOI: 10.1111/tid.13287] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
207 Janik MK, Wunsch E, Raszeja-Wyszomirska J, Moskwa M, Kruk B, Krawczyk M, Milkiewicz P. Autoimmune hepatitis exerts a profound, negative effect on health-related quality of life: A prospective, single-centre study. Liver Int 2019;39:215-21. [PMID: 30204306 DOI: 10.1111/liv.13960] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
208 Ebadi M, Bhanji RA, Mazurak VC, Lytvyak E, Mason A, Czaja AJ, Montano-loza AJ. Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis. Aliment Pharmacol Ther 2019;49:173-82. [DOI: 10.1111/apt.15029] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
209 Efe C, Taii HA, Ytting H, Aehling N, Bhanji RA, Hagström H, Purnak T, Muratori L, Werner M, Muratori P, Klintman D, Schiano TD, Montano-loza AJ, Berg T, Larsen FS, Alkhouri N, Ozaslan E, Heneghan MA, Yoshida EM, Wahlin S. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis. Dig Dis Sci 2018;63:1348-54. [DOI: 10.1007/s10620-018-5011-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
210 Terziroli Beretta-Piccoli B, Vergani D, Mieli-Vergani G. Autoimmune sclerosing cholangitis: Evidence and open questions. J Autoimmun 2018;95:15-25. [PMID: 30366655 DOI: 10.1016/j.jaut.2018.10.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
211 Chung Y, Rahim MN, Graham JJ, Zen Y, Heneghan MA. An update on the pharmacological management of autoimmune hepatitis. Expert Opin Pharmacother 2021;22:1475-88. [PMID: 33624559 DOI: 10.1080/14656566.2021.1895747] [Reference Citation Analysis]
212 Behairy OGA. Characteristics of autoimmune hepatitis in a sample of Egyptian children. Egyptian Pediatric Association Gazette 2017;65:108-13. [DOI: 10.1016/j.epag.2017.11.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
213 Valgeirsson KB, Hreinsson JP, Björnsson ES. Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs. Liver Int 2019;39:2341-9. [PMID: 31436903 DOI: 10.1111/liv.14224] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
214 Taylor SA, Assis DN, Mack CL. The Contribution of B Cells in Autoimmune Liver Diseases. Semin Liver Dis 2019;39:422-31. [PMID: 31226726 DOI: 10.1055/s-0039-1688751] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
215 Snijders RJ, Milkiewicz P, Schramm C, Gevers TJ. Health-related quality of life in autoimmune hepatitis. World J Hepatol 2021; 13(11): 1642-1652 [PMID: 34904034 DOI: 10.4254/wjh.v13.i11.1642] [Reference Citation Analysis]
216 Tadokoro T, Morishita A, Masaki T. Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA. Int J Mol Sci 2021;22:8139. [PMID: 34360904 DOI: 10.3390/ijms22158139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
217 Lopetuso LR, Mocci G, Marzo M, D'Aversa F, Rapaccini GL, Guidi L, Armuzzi A, Gasbarrini A, Papa A. Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver. Int J Mol Sci 2018;19:E2199. [PMID: 30060508 DOI: 10.3390/ijms19082199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
218 Wahlin S, Efe C. Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis. J Hepatol 2021;74:753-5. [PMID: 33309114 DOI: 10.1016/j.jhep.2020.09.016] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
219 Guirguis J, Alonso Y, Lopez R, Carey W. Well-controlled autoimmune hepatitis treatment withdrawal may be safely accomplished without liver-biopsy guidance. Gastroenterol Rep (Oxf) 2018;6:284-90. [PMID: 30430017 DOI: 10.1093/gastro/goy020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
220 Tu H, Chen D, Cai C, Du Q, Lin H, Pan T, Sheng L, Xu Y, Teng T, Tu J, Lin Z, Wang X, Wang R, Xu L, Chen Y. microRNA-143-3p attenuated development of hepatic fibrosis in autoimmune hepatitis through regulation of TAK1 phosphorylation. J Cell Mol Med 2020;24:1256-67. [PMID: 31808606 DOI: 10.1111/jcmm.14750] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
221 Gaber Y, AbdAllah M, Salama A, Sayed M, Abdel Alem S, Nafady S. Metabolic-associated fatty liver disease and autoimmune hepatitis: an overlooked interaction. Expert Rev Gastroenterol Hepatol 2021;:1-9. [PMID: 34263707 DOI: 10.1080/17474124.2021.1952867] [Reference Citation Analysis]
222 Stirnimann G, Ebadi M, Czaja AJ, Montano‐loza AJ. Recurrent and De Novo Autoimmune Hepatitis. Liver Transpl 2019;25:152-66. [DOI: 10.1002/lt.25375] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 9.7] [Reference Citation Analysis]
223 Rutter K, Horvatits T, Drolz A, Roedl K, Siedler S, Kluge S, Fuhrmann V. [Acute liver failure]. Wien Klin Mag 2019;22:38-47. [PMID: 32288865 DOI: 10.1007/s00740-018-0243-0] [Reference Citation Analysis]
224 You Z, Li Y, Wang Q, Zhao Z, Li Y, Qian Q, Li B, Zhang J, Huang B, Liang J, Chen R, Lyu Z, Chen Y, Lian M, Xiao X, Miao Q, Fang J, Lian Z, Eric Gershwin M, Tang R, Ma X. The Clinical Significance of Hepatic CD69+ CD103+ CD8+ Resident-Memory T Cells in Autoimmune Hepatitis. Hepatology 2021;74:847-63. [PMID: 33554350 DOI: 10.1002/hep.31739] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
225 Coenen S, Tran K, de Haan J, de Man R. Liver transplantation for non-exertional heat stroke-related acute liver failure. BMJ Case Rep 2017;2017:bcr-2017-221029. [PMID: 28978590 DOI: 10.1136/bcr-2017-221029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
226 Lammert C, Chalasani SN, Atkinson EJ, McCauley BM, Lazaridis KN. Environmental risk factors are associated with autoimmune hepatitis. Liver Int 2021;41:2396-403. [PMID: 33978301 DOI: 10.1111/liv.14944] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
227 Minghui Z, Kunhua H, Yunwen B, Hongmei L, Jing L, Shaowen W, Longqiaozi S, Chaohui D. Analysis of Differentially Expressed Proteins Involved in Autoimmune Cirrhosis and Normal Serum by iTRAQ Proteomics. Proteomics Clin Appl 2019;13:e1700153. [PMID: 29999587 DOI: 10.1002/prca.201700153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
228 Kapila N, Ma Q, King LY. It Ain't Over Till It's Over. Clin Liver Dis (Hoboken) 2020;16:33-7. [PMID: 32922746 DOI: 10.1002/cld.961] [Reference Citation Analysis]
229 Stine JG, Northup PG. Autoimmune-like drug-induced liver injury: a review and update for the clinician. Expert Opinion on Drug Metabolism & Toxicology 2016;12:1291-301. [DOI: 10.1080/17425255.2016.1211110] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
230 Lytton SD, Osiecki M, Małgorzatawoźniak, Cukrowska B, Wierzbicka A, Goliszek M, Socha P, Janczyk W, Dayanakli D, Abendroth D, Kramp S, Fechner K, Scheper T, Mahler M, Bentow C, Bogdanos D, Fuchs D, Woynarowski M. Tryptophan-kynurenine profile in pediatric autoimmune hepatitis. Immunol Res 2019;67:39-47. [DOI: 10.1007/s12026-019-9068-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
231 Fricker ZP, Lichtenstein DR. Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management. Dig Dis Sci 2019;64:632-42. [PMID: 30725292 DOI: 10.1007/s10620-019-05484-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
232 Schulz L, Sebode M, Schramm C, Lohse AW. [European Reference Network for Rare Hepatological Diseases (ERN RARE-LIVER)]. Internist (Berl) 2021;62:441-8. [PMID: 33687527 DOI: 10.1007/s00108-021-00986-2] [Reference Citation Analysis]
233 Miao Q, Yan L, Zhou Y, Li Y, Zou Y, Wang L, Bai Y, Zhang J. Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprine-induced myelosuppression in southwest china patients with autoimmune hepatitis. Sci Rep 2021;11:7984. [PMID: 33846471 DOI: 10.1038/s41598-021-87095-0] [Reference Citation Analysis]
234 Henze L, Schwinge D, Schramm C. The Effects of Androgens on T Cells: Clues to Female Predominance in Autoimmune Liver Diseases? Front Immunol 2020;11:1567. [PMID: 32849531 DOI: 10.3389/fimmu.2020.01567] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
235 Narciso-Schiavon JL, Schiavon LL. To screen or not to screen? Celiac antibodies in liver diseases. World J Gastroenterol 2017; 23(5): 776-791 [PMID: 28223722 DOI: 10.3748/wjg.v23.i5.776] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
236 Xu J, Chen D, Jin L, Chen Z, Tu Y, Huang X, Xue F, Xu J, Chen M, Wang X, Chen Y. Ubiquitously specific protease 4 inhibitor-Vialinin A attenuates inflammation and fibrosis in S100-induced hepatitis mice through Rheb/mTOR signalling. J Cell Mol Med 2021;25:1140-50. [PMID: 33295107 DOI: 10.1111/jcmm.16180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Vesterhus M, Karlsen TH. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. J Gastroenterol 2020;55:588-614. [PMID: 32222826 DOI: 10.1007/s00535-020-01681-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
238 Hu PF, Wang PQ, Chen H, Hu XF, Xie QP, Shi J, Lin L, Xie WF. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury: Corticosteroid use in drug-induced liver injury. Journal of Digestive Diseases 2016;17:618-27. [DOI: 10.1111/1751-2980.12383] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
239 Moon AM, Spiritos Z, King LY, Barritt AS 4th. Immunosuppression in Autoimmune Hepatitis: Is There an End Game? Am J Gastroenterol 2020;115:498-501. [PMID: 32032074 DOI: 10.14309/ajg.0000000000000538] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
240 Sharma R, Verna EC, Söderling J, Roelstraete B, Hagström H, Ludvigsson JF. Increased Mortality Risk in Autoimmune Hepatitis: A Nationwide Population-Based Cohort Study With Histopathology. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31395-1. [PMID: 33065308 DOI: 10.1016/j.cgh.2020.10.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
241 Lammert C, McKinnon EJ, Chalasani N, Phillips EJ. Novel HLA Class I Alleles Outside the Extended DR3 Haplotype Are Protective against Autoimmune Hepatitis. Clin Transl Gastroenterol 2019;10:e00032. [PMID: 31211758 DOI: 10.14309/ctg.0000000000000032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
242 Theocharidou E, Heneghan MA. Current and future perspectives in autoimmune hepatitis. Br J Hosp Med (Lond) 2018;79:151-9. [PMID: 29528732 DOI: 10.12968/hmed.2018.79.3.151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
243 Mathur K, Vuppalanchi V, Gelow K, Vuppalanchi R, Lammert C. Cannabidiol (CBD) Consumption and Perceived Impact on Extrahepatic Symptoms in Patients with Autoimmune Hepatitis. Dig Dis Sci 2020;65:322-8. [PMID: 31363952 DOI: 10.1007/s10620-019-05756-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
244 Grønbaek H, Kreutzfeldt M, Kazankov K, Jessen N, Sandahl T, Hamilton-dutoit S, Vilstrup H, J. Møller H. Single-centre experience of the macrophage activation marker soluble (s)CD163 - associations with disease activity and treatment response in patients with autoimmune hepatitis. Aliment Pharmacol Ther 2016;44:1062-70. [DOI: 10.1111/apt.13801] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
245 Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, Garcia de la Torre I, Herold M, Klotz W, Cruvinel WM, Mimori T, von Muhlen C, Satoh M, Chan EK. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis 2019;78:879-89. [PMID: 30862649 DOI: 10.1136/annrheumdis-2018-214436] [Cited by in Crossref: 86] [Cited by in F6Publishing: 73] [Article Influence: 28.7] [Reference Citation Analysis]
246 Hartl J, Denzer U, Ehlken H, Zenouzi R, Peiseler M, Sebode M, Hübener S, Pannicke N, Weiler-Normann C, Quaas A. Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. J Hepatol. 2016;65:769-775. [PMID: 27238753 DOI: 10.1016/j.jhep.2016.05.023] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 12.3] [Reference Citation Analysis]
247 Couto CA, Terrabuio DRB, Cançado ELR, Porta G, Levy C, Silva AEB, Bittencourt PL, Carvalho Filho RJD, Chaves DM, Miura IK, Codes L, Faria LC, Evangelista AS, Farias AQ, Gonçalves LL, Harriz M, Lopes EPDA, Luz GO, Oliveira PMC, Oliveira EMG, Schiavon JLN, Sevá-pereira T. UPDATE OF THE BRAZILIAN SOCIETY OF HEPATOLOGY RECOMMENDATIONS FOR DIAGNOSIS AND MANAGEMENT OF AUTOIMMUNE DISEASES OF THE LIVER. Arq Gastroenterol 2019;56:232-41. [DOI: 10.1590/s0004-2803.201900000-43] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
248 Zeng X, Li S, Tang S, Li X, Zhang G, Li M, Zeng X, Hu C. Changes of Serum IgG Glycosylation Patterns in Primary Biliary Cholangitis Patients. Front Immunol 2021;12:669137. [PMID: 34248947 DOI: 10.3389/fimmu.2021.669137] [Reference Citation Analysis]
249 Gerussi A, Halliday N, Saffioti F, Bernasconi DP, Roccarina D, Marshall A, Thorburn D. Normalization of serum immunoglobulin G levels is associated with improved transplant-free survival in patients with autoimmune hepatitis. Digestive and Liver Disease 2020;52:761-7. [DOI: 10.1016/j.dld.2020.04.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
250 Meunier L, Ursic-Bedoya J, Pageaux GP, Larrey D. Pantoprazole-induced autoimmune chronic hepatitis. Liver Int 2018;38:995-9. [PMID: 29532602 DOI: 10.1111/liv.13737] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
251 Sebode M, Wigger J, Filpe P, Fischer L, Weidemann S, Krech T, Weiler-Normann C, Peiseler M, Hartl J, Tolosa E, Herkel J, Schramm C, Lohse AW, Arrenberg P. Inflammatory Phenotype of Intrahepatic Sulfatide-Reactive Type II NKT Cells in Humans With Autoimmune Hepatitis. Front Immunol 2019;10:1065. [PMID: 31191516 DOI: 10.3389/fimmu.2019.01065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
252 Díaz-Ramírez GS, Marín-Zuluaga JI, Donado-Gómez JH, Muñoz-Maya O, Santos-Sánchez Ó, Restrepo-Gutiérrez JC. Characterization of patients with autoimmune hepatitis at an university hospital in Medellín-Colombia: cohort study. Gastroenterol Hepatol 2018;41:87-96. [PMID: 29126693 DOI: 10.1016/j.gastrohep.2017.09.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
253 Aljumah AA, Al Jarallah B, Albenmousa A, Al Khathlan A, Al Zanbagi A, Al Quaiz M, Al-Judaibi B, Nabrawi K, Al Hamoudi W, Alghamdi M, Fallatah H. The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitis. Saudi J Gastroenterol 2018;24:S1-S20. [PMID: 30264737 DOI: 10.4103/sjg.SJG_159_18] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
254 Lowe D, John S. Autoimmune hepatitis: Appraisal of current treatment guidelines. World J Hepatol 2018; 10(12): 911-923 [PMID: 30631396 DOI: 10.4254/wjh.v10.i12.911] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
255 Buettner N, Thimme R. Sexual dimorphism in hepatitis B and C and hepatocellular carcinoma. Semin Immunopathol 2019;41:203-11. [PMID: 30498927 DOI: 10.1007/s00281-018-0727-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
256 Lammert C, Chalasani SN, Green K, Atkinson E, McCauley B, Lazaridis KN. Patients with Autoimmune Hepatitis Report Lower Lifetime Coffee Consumption. Dig Dis Sci 2021. [PMID: 33939140 DOI: 10.1007/s10620-021-06989-1] [Reference Citation Analysis]
257 Neuberger J, Cain O. The Need for Alternatives to Liver Biopsies: Non-Invasive Analytics and Diagnostics. Hepat Med 2021;13:59-69. [PMID: 34163263 DOI: 10.2147/HMER.S278076] [Reference Citation Analysis]
258 Hartl J, Miquel R, Zachou K, Wong GW, Asghar A, Pape S, Sebode M, Peiseler M, Zenouzi R, Ehlken H, Krech T, Weiler-Normann C, Drenth JPH, Oo YH, Dalekos GN, Heneghan M, Schramm C, Lohse AW. Features and outcome of AIH patients without elevation of IgG. JHEP Rep 2020;2:100094. [PMID: 32280942 DOI: 10.1016/j.jhepr.2020.100094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
259 Umemura T, Joshita S, Saito H, Yoshizawa K, Norman GL, Tanaka E, Ota M. KIR/HLA genotypes confer susceptibility and progression in patients with autoimmune hepatitis. JHEP Rep 2019;1:353-60. [PMID: 32039386 DOI: 10.1016/j.jhepr.2019.09.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
260 Dumortier J, Chouik Y, Hequet O, Hervieu V, Boillot O. Rituximab and plasmapheresis for severe post-transplant auto-immune hepatitis. Clin Res Hepatol Gastroenterol 2021;:101844. [PMID: 34920142 DOI: 10.1016/j.clinre.2021.101844] [Reference Citation Analysis]
261 Eriksen PL, Kreutzfeldt M, Grønbaek H, Thorsen K, Vang S, Jessen N, Vilstrup H. Enrichment of Genetic Variants in the Glucocorticoid Receptor Signalling Pathway in Autoimmune Hepatitis with Failure of Standard Treatment. Basic Clin Pharmacol Toxicol 2017;121:189-94. [DOI: 10.1111/bcpt.12788] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
262 González-Regueiro JA, Cruz-Contreras M, Merayo-Chalico J, Barrera-Vargas A, Ruiz-Margáin A, Campos-Murguía A, Espin-Nasser M, Martínez-Benítez B, Méndez-Cano VH, Macías-Rodríguez RU. Hepatic manifestations in systemic lupus erythematosus. Lupus 2020;29:813-24. [PMID: 32390496 DOI: 10.1177/0961203320923398] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
263 Zhou T, Fronhoffs F, Dold L, Strassburg CP, Weismüller TJ. New-onset autoimmune hepatitis following mRNA COVID-19 vaccination in a 36-year-old woman with primary sclerosing cholangitis - should we be more vigilant? J Hepatol 2021:S0168-8278(21)02000-6. [PMID: 34450237 DOI: 10.1016/j.jhep.2021.08.006] [Reference Citation Analysis]
264 Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME. The challenges of primary biliary cholangitis: What is new and what needs to be done. J Autoimmun 2019;105:102328. [PMID: 31548157 DOI: 10.1016/j.jaut.2019.102328] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
265 Hippchen T, Sauer P, Göppert B, Schirmacher P, Gotthardt DN, Weiss KH, Stremmel W, Rupp C. Association between serum IgG level and clinical course in primary sclerosing cholangitis. BMC Gastroenterol 2019;19:153. [PMID: 31455255 DOI: 10.1186/s12876-019-1075-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
266 Björnsson ES, Kalaitzakis E. Recent advances in the treatment of primary sclerosing cholangitis. Expert Rev Gastroenterol Hepatol 2021;15:413-25. [PMID: 33283566 DOI: 10.1080/17474124.2021.1860751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
267 Renand A, Habes S, Mosnier JF, Aublé H, Judor JP, Vince N, Hulin P, Nedellec S, Métairie S, Archambeaud I, Brouard S, Gournay J, Conchon S. Immune Alterations in Patients With Type 1 Autoimmune Hepatitis Persist Upon Standard Immunosuppressive Treatment. Hepatol Commun 2018;2:968-81. [PMID: 30094407 DOI: 10.1002/hep4.1202] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
268 Hupa-Breier KL, Taubert R, Jaeckel E, Manns MP. Editorial: "real world data" of AIH-time to connect! Aliment Pharmacol Ther 2018;48:1315-6. [PMID: 30488627 DOI: 10.1111/apt.15028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
269 Schultheiß C, Simnica D, Willscher E, Oberle A, Fanchi L, Bonzanni N, Wildner NH, Schulze Zur Wiesch J, Weiler-Normann C, Lohse AW, Binder M. Next-Generation Immunosequencing Reveals Pathological T-Cell Architecture in Autoimmune Hepatitis. Hepatology 2021;73:1436-48. [PMID: 32692457 DOI: 10.1002/hep.31473] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
270 Handzlik-Orlik G, Holecki M, Wilczyński K, Duława J. Osteoporosis in liver disease: pathogenesis and management. Ther Adv Endocrinol Metab 2016;7:128-35. [PMID: 27293541 DOI: 10.1177/2042018816641351] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
271 Janik MK, Kruk B, Szczepankiewicz B, Kostrzewa K, Raszeja-Wyszomirska J, Górnicka B, Lammert F, Milkiewicz P, Krawczyk M. Measurement of liver and spleen stiffness as complementary methods for assessment of liver fibrosis in autoimmune hepatitis. Liver Int 2021;41:348-56. [PMID: 33159831 DOI: 10.1111/liv.14726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
272 Baven-Pronk MAMC, Biewenga M, van Silfhout JJ, van den Berg AP, van Buuren HR, Verwer BJ, van Nieuwkerk CMJ, Bouma G, van Hoek B. Role of age in presentation, response to therapy and outcome of autoimmune hepatitis. Clin Transl Gastroenterol. 2018;9:165. [PMID: 29961755 DOI: 10.1038/s41424-018-0028-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
273 Ben Merabet Y, Barbe C, Heurgue-Berlot A, Thévenot T, Minello A, Habersetzer F, Samuel D, Bernard-Chabert B, Weil-Verhoeven D, Renard P, Clot H, Di Martino V, Louvet H, Bresson-Hadni S, Thiéfin G. Sustained Remission After Treatment Withdrawal in Autoimmune Hepatitis: A Multicenter Retrospective Study. Dig Dis Sci 2021;66:2107-17. [PMID: 32607807 DOI: 10.1007/s10620-020-06444-7] [Reference Citation Analysis]
274 Crismale JF, Friedman SL. Acute Liver Injury and Decompensated Cirrhosis. Med Clin North Am 2020;104:647-62. [PMID: 32505258 DOI: 10.1016/j.mcna.2020.02.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
275 Terziroli Beretta-piccoli B, Mieli-vergani G, Vergani D. The clinical usage and definition of autoantibodies in immune-mediated liver disease: A comprehensive overview. Journal of Autoimmunity 2018;95:144-58. [DOI: 10.1016/j.jaut.2018.10.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
276 Doycheva I, Watt KD, Gulamhusein AF. Autoimmune hepatitis: Current and future therapeutic options. Liver Int 2019;39:1002-13. [DOI: 10.1111/liv.14062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
277 Puustinen L, Boyd S, Arkkila P, Isoniemi H, Arola J, Färkkilä M. Histologic surveillance after liver transplantation due to autoimmune hepatitis. Clin Transplant 2017;31:e12936. [DOI: 10.1111/ctr.12936] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
278 Fan X, Men R, Wang H, Shen M, Wang T, Ye T, Luo X, Yang L. Methylprednisolone Decreases Mitochondria-Mediated Apoptosis and Autophagy Dysfunction in Hepatocytes of Experimental Autoimmune Hepatitis Model via the Akt/mTOR Signaling. Front Pharmacol. 2019;10:1189. [PMID: 31680966 DOI: 10.3389/fphar.2019.01189] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
279 Hartl J, Ehlken H, Sebode M, Peiseler M, Krech T, Zenouzi R, von Felden J, Weiler-Normann C, Schramm C, Lohse AW. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. J Hepatol. 2017; Epub ahead of print. [PMID: 29180000 DOI: 10.1016/j.jhep.2017.11.020] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 9.4] [Reference Citation Analysis]
280 Braga A, Braga J. Successful pregnancy with autoimmune cirrhosis. BMJ Case Rep 2016;2016:bcr2015212501. [PMID: 26825934 DOI: 10.1136/bcr-2015-212501] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
281 Cai X, Weng HH, Miao LY. Yinzhihuang injection for treatment of patients with autoimmune hepatitis: Clinical efficacy and impact on hepatic fibrosis indexes. Shijie Huaren Xiaohua Zazhi 2017; 25(8): 726-731 [DOI: 10.11569/wcjd.v25.i8.726] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
282 Jeong SH. Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea. Clin Mol Hepatol 2018;24:10-9. [PMID: 29307132 DOI: 10.3350/cmh.2017.0066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
283 Castellanos Fernández MI, Cepeda Mullo ME, la Rosa Hernández D, Vega Sánchez H, González Fabian L, Gish RG, Torres González AL, Dorta Guridi Z. Autoimmune Hepatitis in Cuban Patients: A Retrospective Analysis of Clinical and Histological Profiles, Treatments, and Outcomes. Curr Ther Res Clin Exp 2020;93:100594. [PMID: 32922567 DOI: 10.1016/j.curtheres.2020.100594] [Reference Citation Analysis]
284 Ibraheem MF, Ahmed SJ. The association between juvenile autoimmune hepatitis and HLA-DRB1 alleles: Iraqi tertiary center experience. Clin Exp Hepatol 2021;7:178-82. [PMID: 34295985 DOI: 10.5114/ceh.2021.106865] [Reference Citation Analysis]
285 Manns MP, Jaeckel E, Taubert R. Budesonide in Autoimmune Hepatitis: The Right Drug at the Right Time for the Right Patient. Clin Gastroenterol Hepatol 2018;16:186-9. [PMID: 29128475 DOI: 10.1016/j.cgh.2017.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
286 Albright CM, Fay EE. Chronic Liver Disease in the Obstetric Patient. Clin Obstet Gynecol 2020;63:193-210. [PMID: 31789831 DOI: 10.1097/GRF.0000000000000502] [Reference Citation Analysis]
287 De Martin E, Duclos-Vallée JC. Reply to: "Acute severe autoimmune hepatitis - timing for steroids and role of other immunosuppressive agents". J Hepatol 2021;75:495-6. [PMID: 34051331 DOI: 10.1016/j.jhep.2021.05.010] [Reference Citation Analysis]
288 Gaspar R, Rodrigues S, Silva M, Costa-Moreira P, Morais R, Andrade P, Cardoso H, Albuquerque A, Liberal R, Macedo G. Predictive models of mortality and hospital readmission of patients with decompensated liver cirrhosis. Dig Liver Dis 2019;51:1423-9. [PMID: 31113738 DOI: 10.1016/j.dld.2019.03.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
289 Lleo A, de Boer YS, Liberal R, Colombo M. The risk of liver cancer in autoimmune liver diseases. Ther Adv Med Oncol 2019;11:1758835919861914. [PMID: 31320937 DOI: 10.1177/1758835919861914] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
290 Zizzo AN, Jimenez-Rivera C, Kim J, Schreiber RA, Ling SC, Yap J, Critch J, Ahmed N, Alvarez F, Kamath BM; Canadian Paediatric Hepatology Research Group (CPHRG). A national retrospective study of paediatric end-stage liver disease as a predictor of change to second-line therapy in children with autoimmune hepatitis. Liver Int 2017;37:1562-70. [PMID: 28199778 DOI: 10.1111/liv.13387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
291 Li X, Xu H, Gao P. Red Blood Cell Distribution Width-to-Platelet Ratio and Other Laboratory Indices Associated with Severity of Histological Hepatic Fibrosis in Patients with Autoimmune Hepatitis: A Retrospective Study at a Single Center. Med Sci Monit 2020;26:e927946. [PMID: 33180750 DOI: 10.12659/MSM.927946] [Reference Citation Analysis]
292 Nayagam JS, Heneghan MA, Samyn M, Joshi D. Editorial: testing for Epstein Barr virus and treating autoimmune hepatitis-still a long way to go! Authors' reply. Aliment Pharmacol Ther 2022;55:366-7. [PMID: 35040167 DOI: 10.1111/apt.16759] [Reference Citation Analysis]
293 Joshita S, Yoshizawa K, Umemura T, Ohira H, Takahashi A, Harada K, Hiep NC, Tsuneyama K, Kage M, Nakano M, Kang JH, Koike K, Zeniya M, Yasunaka T, Takaki A, Torimura T, Abe M, Yokosuka O, Tanaka A, Takikawa H; Japan Autoimmune Hepatitis Study Group (JAIHSG). Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey. J Gastroenterol 2018;53:1079-88. [PMID: 29476251 DOI: 10.1007/s00535-018-1444-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
294 Trivedi PJ, Hubscher SG, Heneghan M, Gleeson D, Hirschfield GM. Grand round: Autoimmune hepatitis. J Hepatol 2019;70:773-84. [PMID: 30465775 DOI: 10.1016/j.jhep.2018.11.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
295 Wang Y, Xu X, Ran M, Guo X, Zhou L, Wang X, Wang B, Zhang J. The Enlargement of Abdominal Lymph Nodes Is a Characteristic of Autoimmune Liver Disease. Mediators Inflamm 2020;2020:3631625. [PMID: 32273828 DOI: 10.1155/2020/3631625] [Reference Citation Analysis]
296 Riveiro-Barciela M, Barreira-Díaz A, Vidal-González J, Muñoz-Couselo E, Martínez-Valle F, Viladomiu L, Mínguez B, Ortiz-Velez C, Castells L, Esteban R, Buti M. Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors.Liver Int. 2020;40:1906-1916. [PMID: 32329119 DOI: 10.1111/liv.14489] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
297 El Jamaly H, Eslick GD, Weltman M. Systematic review with meta-analysis: autoimmune hepatitis in pregnancy. Scand J Gastroenterol 2021;:1-11. [PMID: 34396871 DOI: 10.1080/00365521.2021.1953127] [Reference Citation Analysis]
298 Kalafateli M, Triantos C, Tsamandas A, Dalekos GN. Spontaneous Cirrhosis Regression in an IFN-beta-induced AIH-like Syndrome Following Drug Withdrawal: Art of Facts or Artifacts? Eur J Case Rep Intern Med 2016;3:000396. [PMID: 30755872 DOI: 10.12890/2016_000396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
299 Wang H, Feng X, Yan W, Tian D. Regulatory T Cells in Autoimmune Hepatitis: Unveiling Their Roles in Mouse Models and Patients. Front Immunol 2020;11:575572. [PMID: 33117375 DOI: 10.3389/fimmu.2020.575572] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
300 Deibert P, Lazaro A, Stankovic Z, Schaffner D, Rössle M, Kreisel W. Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up. World J Gastroenterol 2018; 24(3): 438-444 [PMID: 29391766 DOI: 10.3748/wjg.v24.i3.438] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
301 Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671-722. [PMID: 31863477 DOI: 10.1002/hep.31065] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 52.0] [Reference Citation Analysis]
302 Beer A, Dienes HP. Autoimmune hepatitis-is histology conclusive? Ann Transl Med 2021;9:733. [PMID: 33987431 DOI: 10.21037/atm-20-5084] [Reference Citation Analysis]
303 T de Moraes Falcão L, Terrabuio DRB, Diniz MA, da Silva Evangelista A, Souza FG, R Cancado EL. Efficacy and safety of chloroquine plus prednisone for the treatment of autoimmune hepatitis in a randomized trial. JGH Open 2020;4:371-7. [PMID: 32514439 DOI: 10.1002/jgh3.12258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
304 Lammert C, Loy VM, Oshima K, Gawrieh S. Management of Difficult Cases of Autoimmune Hepatitis. Curr Gastroenterol Rep. 2016;18:9. [PMID: 26780632 DOI: 10.1007/s11894-015-0484-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
305 Ebadi M, Czaja AJ, Montano-Loza AJ. Letter: vitamin D deficiency and autoimmune hepatitis - from research to treatment-authors' reply. Aliment Pharmacol Ther 2019;49:1104-5. [PMID: 30920035 DOI: 10.1111/apt.15154] [Reference Citation Analysis]
306 Sartini A, Gitto S, Bianchini M, Verga MC, Di Girolamo M, Bertani A, Del Buono M, Schepis F, Lei B, De Maria N, Villa E. Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. Cell Death Dis. 2018;9:87. [PMID: 29367619 DOI: 10.1038/s41419-017-0124-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
307 Carrier P, Debette-Gratien M, Jacques J, Loustaud-Ratti V. Cirrhotic patients and older people. World J Hepatol 2019; 11(9): 663-677 [PMID: 31598192 DOI: 10.4254/wjh.v11.i9.663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
308 Nguyen HH, Shaheen AA, Baeza N, Lytvyak E, Urbanski SJ, Mason AL, Norman GL, Fritzler MJ, Swain MG. Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS). PLoS One 2018;13:e0193960. [PMID: 29554146 DOI: 10.1371/journal.pone.0193960] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
309 Schwinge D, Schramm C. Sex-related factors in autoimmune liver diseases. Semin Immunopathol 2019;41:165-75. [DOI: 10.1007/s00281-018-0715-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
310 Dalekos GN, Gatselis NK, Zachou K, Koukoulis GK. NAFLD and autoimmune hepatitis: Do not judge a book by its cover. Eur J Intern Med 2020;75:1-9. [PMID: 32051092 DOI: 10.1016/j.ejim.2020.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
311 Paolella G, Farallo M, Degrassi I, Agostoni C, Amoruso C, Nuti F, Nebbia G. Pediatric autoimmune liver disease and extra-hepatic immune-mediated comorbidities. Dig Liver Dis 2019;51:281-5. [PMID: 30166220 DOI: 10.1016/j.dld.2018.07.033] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
312 Pape S, Gevers TJG, Vrolijk JM, van Hoek B, Bouma G, van Nieuwkerk CMJ, Taubert R, Jaeckel E, Manns MP, Papp M, Sipeki N, Stickel F, Efe C, Ozaslan E, Purnak T, Nevens F, Kessener DJN, Kahraman A, Wedemeyer H, Hartl J, Schramm C, Lohse AW, Drenth JPH, Heneghan MA. Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months. Clin Gastroenterol Hepatol 2020;18:1609-1617.e4. [PMID: 31715274 DOI: 10.1016/j.cgh.2019.11.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
313 Vesterhus M, Nielsen MJ, Hov JR, Saffioti F, Manon-Jensen T, Leeming DJ, Moum B, Boberg KM, Pinzani M, Karlsen TH, Karsdal MA, Thorburn D. Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease. JHEP Rep 2021;3:100178. [PMID: 33225252 DOI: 10.1016/j.jhepr.2020.100178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
314 Dalekos GN, Koskinas J, Papatheodoridis GV. Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis. Ann Gastroenterol 2019;32:1-23. [PMID: 30598587 DOI: 10.20524/aog.2018.0330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
315 Teles C, Santos R, Silva CD, Vaio T. Postinfantile giant cell hepatitis in the setting of autoimmune hepatitis: exclusively a histological pattern or a prognosis predictor? BMJ Case Rep 2021;14:e243660. [PMID: 34290027 DOI: 10.1136/bcr-2021-243660] [Reference Citation Analysis]
316 Wu H, Tang S, Zhou M, Xue J, Yu Z, Zhu J. Tim-3 suppresses autoimmune hepatitis via the p38/MKP-1 pathway in Th17 cells. FEBS Open Bio 2021;11:1406-16. [PMID: 33728805 DOI: 10.1002/2211-5463.13148] [Reference Citation Analysis]
317 Efe C, Dhanasekaran R, Lammert C, Ebik B, Higuera-de la Tijera F, Aloman C, Rıza Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Gomez Aldana AJ, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kıyıcı M, Akyıldız M, Ekin N, Carr RM, Harputluoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, Assis DN, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology 2021;73:2099-109. [PMID: 33713486 DOI: 10.1002/hep.31797] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
318 Buzzetti E, Parikh PM, Gerussi A, Tsochatzis E. Gender differences in liver disease and the drug-dose gender gap. Pharmacol Res 2017;120:97-108. [PMID: 28336373 DOI: 10.1016/j.phrs.2017.03.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
319 Zhang HP, Liu YM, Li Z, Ma YX, Li LJ, Zhao DT, Lou JL, Gao ZH, Yan HP. Clinical characteristics and HLA genotypes in Chinese patients with anti-SLA/LP-positive autoimmune hepatitis. Ann Transl Med 2021;9:153. [PMID: 33569455 DOI: 10.21037/atm-20-8036] [Reference Citation Analysis]
320 Sasamori Y, Tanaka A, Ayabe T. Liver disease in pregnancy. Hepatol Res 2020;50:1015-23. [PMID: 32583511 DOI: 10.1111/hepr.13540] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
321 Habes S, Gournay J, Milpied P, Conchon S, Renand A. [Peculiar profile of auto-reactive T lymphocytes in auto-immune hepatitis]. Med Sci (Paris) 2021;37:326-9. [PMID: 33908849 DOI: 10.1051/medsci/2021027] [Reference Citation Analysis]
322 Zachou K, Lygoura V, Arvaniti P, Giannoulis G, Gatselis NK, Koukoulis GK, Dalekos GN. FibroMeter scores for the assessment of liver fibrosis in patients with autoimmune liver diseases. Ann Hepatol 2021;22:100285. [PMID: 33157268 DOI: 10.1016/j.aohep.2020.10.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
323 Derben FC, Engel B, Zachou K, Hartl J, Hartleben B, Bantel H, Schramm C, Dalekos GN, Manns MP, Jaeckel E, Taubert R. CK-18 cell death markers improve the prediction of histological remission in autoimmune hepatitis during biochemical remission. Liver Int 2021;41:123-7. [PMID: 33043565 DOI: 10.1111/liv.14699] [Reference Citation Analysis]
324 Liwinski T, Casar C, Ruehlemann MC, Bang C, Sebode M, Hohenester S, Denk G, Lieb W, Lohse AW, Franke A, Schramm C. A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis. Aliment Pharmacol Ther 2020;51:1417-28. [DOI: 10.1111/apt.15754] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
325 Ikura A, Chu PS, Nakamoto N, Ojiro K, Taniki N, Yoshida A, Shinoda M, Morikawa R, Yamataka K, Noguchi F, Hoshi H, Usui S, Ebinuma H, Kitagawa Y, Saito H, Kanai T. CLIF-C Organ Failure Score and Liver Volume Predict Prognosis in Steroid-Treated Severe Acute Autoimmune Hepatitis. Hepatol Commun 2020;4:1019-33. [PMID: 32626834 DOI: 10.1002/hep4.1521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
326 Torisu Y, Nakano M, Takano K, Nakagawa R, Saeki C, Hokari A, Ishikawa T, Saruta M, Zeniya M. Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis. World J Hepatol 2017; 9(1): 57-63 [PMID: 28105259 DOI: 10.4254/wjh.v9.i1.57] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
327 Ginès P, Graupera I, Lammert F, Angeli P, Caballeria L, Krag A, Guha IN, Murad SD, Castera L. Screening for liver fibrosis in the general population: a call for action. The Lancet Gastroenterology & Hepatology 2016;1:256-60. [DOI: 10.1016/s2468-1253(16)30081-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 19] [Article Influence: 10.2] [Reference Citation Analysis]
328 Schramm C. Autoimmune Hepatitis Beyond Steroids: Effective Trial Design and Attention to Quality of Life. Clin Liver Dis (Hoboken) 2019;14:33-6. [PMID: 31391935 DOI: 10.1002/cld.816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
329 Ter Avest MM, van Hee K, Bronkhorst C, de Jonge HJM. Mesalazine induced autoimmune hepatitis in a patient with Crohn's disease. Clin Res Hepatol Gastroenterol 2020;:101551. [PMID: 33158802 DOI: 10.1016/j.clinre.2020.09.012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
330 Byenfeldt M, Elvin A, Fransson P. Influence of Probe Pressure on Ultrasound-Based Shear Wave Elastography of the Liver Using Comb-Push 2-D Technology. Ultrasound Med Biol 2019;45:411-28. [PMID: 30401508 DOI: 10.1016/j.ultrasmedbio.2018.09.023] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
331 Kang GL, Xu Y, Bao J, Liu XM, Hou YG, Li QL. Clinical features of celiac disease in patients with autoimmune liver disease: Report of 10 cases. Shijie Huaren Xiaohua Zazhi 2017; 25(21): 1968-1975 [DOI: 10.11569/wcjd.v25.i21.1968] [Reference Citation Analysis]
332 Huang C, Xing X, Xiang X, Fan X, Men R, Ye T, Yang L. MicroRNAs in autoimmune liver diseases: from diagnosis to potential therapeutic targets. Biomed Pharmacother 2020;130:110558. [PMID: 32781357 DOI: 10.1016/j.biopha.2020.110558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
333 Cao R, Zhang S, Li J, Zhang J, Zhao Y, Jiao P, Wang C, Guo Z. Chinese Herbal Medicine-Induced Rapid Liver Cirrhosis: A Case Report. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.118934] [Reference Citation Analysis]
334 Valean S, Acalovschi M, Dumitrascu DL, Ciobanu L, Nagy G, Chira R. Hepatocellular carcinoma in patients with autoimmune hepatitis - a systematic review of the literature published between 1989-2016. Med Pharm Rep 2019;92:99-105. [PMID: 31086834 DOI: 10.15386/mpr-1228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
335 Miranda-Zazueta G, González-Regueiro JA, García-Juárez I, Moctezuma-Velázquez C, López-Díaz FJ, Pérez-González B, Uscanga-Domínguez LF, Peláez-Luna M. Pharmacologic management of patients with hepatic and pancreatic diseases that involve immunosuppressive therapies. Position statement within the framework of the SARS-CoV-2 (COVID-19) pandemic. Rev Gastroenterol Mex (Engl Ed) 2020;85:312-20. [PMID: 32620315 DOI: 10.1016/j.rgmx.2020.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
336 Fasano R, Malerba E, Prete M, Solimando AG, Buonavoglia A, Silvestris N, Leone P, Racanelli V. Impact of Antigen Presentation Mechanisms on Immune Response in Autoimmune Hepatitis. Front Immunol 2022;12:814155. [DOI: 10.3389/fimmu.2021.814155] [Reference Citation Analysis]
337 Taubert R, Jaeckel E. [Autoimmune hepatitis-standard and second-line therapy]. Internist (Berl) 2018;59:536-43. [PMID: 29725696 DOI: 10.1007/s00108-018-0434-1] [Reference Citation Analysis]
338 Buitrago-Molina LE, Dywicki J, Noyan F, Trippler M, Pietrek J, Schlue J, Manns MP, Wedemeyer H, Jaeckel E, Hardtke-Wolenski M. Splenectomy Prior to Experimental Induction of Autoimmune Hepatitis Promotes More Severe Hepatic Inflammation, Production of IL-17 and Apoptosis. Biomedicines 2021;9:58. [PMID: 33435354 DOI: 10.3390/biomedicines9010058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
339 Van Hoovels L, Broeders S, Chan EKL, Andrade L, de Melo Cruvinel W, Damoiseaux J, Viander M, Herold M, Coucke W, Heijnen I, Bogdanos D, Calvo-Alén J, Eriksson C, Kozmar A, Kuhi L, Bonroy C, Lauwerys B, Schouwers S, Lutteri L, Vercammen M, Mayer M, Patel D, Egner W, Puolakka K, Tesija-Kuna A, Shoenfeld Y, de Sousa MJR, Hoyos ML, Radice A, Bossuyt X. Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey. Auto Immun Highlights 2020;11:17. [PMID: 33228811 DOI: 10.1186/s13317-020-00139-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
340 Wang H, Wang J, Xia J, Yan X, Feng Y, Li L, Chen J, Liu D, Ding W, Yang Y, Huang R, Wu C. Red cell distribution width to platelet ratio predicts liver fibrosis in patients with autoimmune hepatitis. Medicine (Baltimore) 2020;99:e21408. [PMID: 32846758 DOI: 10.1097/MD.0000000000021408] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
341 Sogo T, Takahashi A, Inui A, Fujisawa T, Ohira H, Takikawa H; Japan AIH Study Group (JAIHSG). Clinical features of pediatric autoimmune hepatitis in Japan: A nationwide survey: Pediatric autoimmune hepatitis in Japan. Hepatol Res 2018;48:286-94. [DOI: 10.1111/hepr.12998] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
342 Zhang W, Liu L, Zhang M, Zhang F, Peng C, Zhang B, Chen J, Li L, He J, Xiao J, Feng Y, Wang X, Xiong A, Yang L, Zou X, Yu Y, Zhuge Y. Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome. J Clin Transl Hepatol 2021;9:345-52. [PMID: 34221920 DOI: 10.14218/JCTH.2020.00124] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
343 Cristoferi L, Nardi A, Invernizzi P, Mells G, Carbone M. Individualizing Care: Management Beyond Medical Therapy. Clin Liver Dis 2018;22:545-61. [PMID: 30259852 DOI: 10.1016/j.cld.2018.03.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
344 Mühling T, Rohrbach H, Schepp W, Gundling F. Overlap of concurrent extrahepatic autoimmune diseases is associated with milder disease severity of newly diagnosed autoimmune hepatitis. Hepatobiliary Pancreat Dis Int 2021;20:21-7. [PMID: 32830050 DOI: 10.1016/j.hbpd.2020.06.019] [Reference Citation Analysis]
345 Dalekos GN, Gatselis NK, Koukoulis GK. Non-alcoholic steatohepatitis or autoimmune hepatitis? Sometimes a closer look under the surface is needed. BMJ Case Rep 2020;13:e238400. [PMID: 33370951 DOI: 10.1136/bcr-2020-238400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
346 Efe C, Ozaslan E, Purnak T. What Is the Optimal Dose of Predniso(lo)ne for Induction of Remission in Patients With Autoimmune Hepatitis? Clin Gastroenterol Hepatol 2020;18:1896-7. [PMID: 30807845 DOI: 10.1016/j.cgh.2019.02.032] [Reference Citation Analysis]
347 Balbi VA, Montenegro B, Pitta AC, Schmidt AR, Farhat SC, Coelho LP, Ferreira JCO, Pereira RMR, Terreri MT, Saad-Magalhães C, Aikawa NE, Sakamoto AP, Kozu K, Campos LM, Sallum AM, Ferriani VP, Piotto DP, Bonfá E, Silva CA. Autoimmune hepatitis in 847 childhood-onset systemic lupus erythematosus population: a multicentric cohort study. Adv Rheumatol 2018;58:43. [PMID: 30657090 DOI: 10.1186/s42358-018-0043-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
348 Tanaka A. Emerging novel treatments for autoimmune liver diseases. Hepatol Res 2019;49:489-99. [PMID: 30969002 DOI: 10.1111/hepr.13347] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
349 Bossen L, Gerussi A, Lygoura V, Mells GF, Carbone M, Invernizzi P. Support of precision medicine through risk-stratification in autoimmune liver diseases – histology, scoring systems, and non-invasive markers. Autoimmunity Reviews 2018;17:854-65. [DOI: 10.1016/j.autrev.2018.02.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
350 Llovet LP, Gratacós-Ginès J, Téllez L, Gómez-Outomuro A, Navascués CA, Riveiro-Barciela M, Vinuesa R, Gómez-Camarero J, García-Retortillo M, Díaz-Fontenla F, Salcedo M, García-Eliz M, Horta D, Guerrero M, Rodríguez-Perálvarez M, Fernández-Rodriguez C, Albillos A, G-Abraldes J, Parés A, Londoño MC. Noninvasive Prediction of Outcomes in Autoimmune Hepatitis-Related Cirrhosis. Hepatol Commun 2022. [PMID: 34989164 DOI: 10.1002/hep4.1889] [Reference Citation Analysis]
351 Orlien SMS, Ahmed TA, Ismael NY, Berhe N, Lauritzen T, Gundersen SG, Johannessen A. High Seroprevalence of Autoantibodies Typical of Autoimmune Liver Disease in Eastern Ethiopia: Is Chewing of Khat (Catha edulis) a Triggering Factor? Can J Gastroenterol Hepatol 2018;2018:4980597. [PMID: 30675469 DOI: 10.1155/2018/4980597] [Reference Citation Analysis]
352 Bolia R, Rajanayagam J, Hardikar W. Lower 6-MMP/6-TG Ratio May Be a Therapeutic Target in Pediatric Autoimmune Hepatitis. J Pediatr Gastroenterol Nutr 2018;67:695-700. [PMID: 30234756 DOI: 10.1097/MPG.0000000000002146] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
353 An J. Expression and Significance of Th17 Cells and Related Factors in Patients with Autoimmune Hepatitis. Comb Chem High Throughput Screen 2019;22:232-7. [PMID: 30947662 DOI: 10.2174/1386207322666190402160455] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
354 Richardson N, Ng STH, Wraith DC. Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases. Front Immunol 2020;11:1586. [PMID: 32793226 DOI: 10.3389/fimmu.2020.01586] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
355 Hsu M, Liu S, Wang C, Hu N, Wu ES, Shih Y, Chiu PJ. JKB-122 is effective, alone or in combination with prednisolone in Con A-induced hepatitis. European Journal of Pharmacology 2017;812:113-20. [DOI: 10.1016/j.ejphar.2017.07.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
356 Lemoinne S, Heurgue A, Bouzbib C, Hanslik B, Gournay J, Nguyen-Khac E, Bureau C, de Lédinghen V, Ganne-Carrié N, Bourlière M. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF AUTOIMMUNE HEPATITIS. Clin Res Hepatol Gastroenterol 2021;:101772. [PMID: 34332126 DOI: 10.1016/j.clinre.2021.101772] [Reference Citation Analysis]
357 Giuffrida P, Aronico N, Rosselli M, Lenti MV, Cococcia S, Roccarina D, Saffioti F, Delliponti M, Thorburn D, Miceli E, Corazza GR, Pinzani M, Di Sabatino A. Defective spleen function in autoimmune gastrointestinal disorders. Intern Emerg Med 2020;15:225-9. [PMID: 31214883 DOI: 10.1007/s11739-019-02129-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
358 Wu S, Yang Z, Zhou J, Zeng N, He Z, Zhan S, Jia J, You H. Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis. Hepatol Int 2019;13:91-101. [PMID: 30443702 DOI: 10.1007/s12072-018-9907-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
359 Biewenga M, Verhelst XPDMJ, Baven-Pronk MAMC, Putter H, van den Berg AP, van Nieuwkerk KCMJ, van Buuren HR, Bouma G, de Boer YS, Simoen C, Colle I, Schouten J, Sermon F, van Steenkiste C, van Vlierberghe H, van der Meer AJ, Nevens F, van Hoek B; Dutch Autoimmune Hepatitis Study Group. Development and validation of a prognostic score for long-term transplant-free survival in autoimmune hepatitis type 1. United European Gastroenterol J 2021;9:662-71. [PMID: 34165262 DOI: 10.1002/ueg2.12112] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
360 Terziroli Beretta-piccoli B, Mieli-vergani G, Vergani D. Serology in autoimmune hepatitis: A clinical-practice approach. European Journal of Internal Medicine 2018;48:35-43. [DOI: 10.1016/j.ejim.2017.10.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
361 Fedrizzi RS, Coral GP, Mattos AA, Mattos ÂZ, Tovo CV. EVALUATION OF PATIENTS WITH AUTOIMMUNE HEPATITIS IN A SPECIALIZED OUTPATIENT CLINIC IN SOUTHERN BRAZIL. Arq Gastroenterol 2020;57:361-5. [PMID: 33237214 DOI: 10.1590/S0004-2803.202000000-69] [Reference Citation Analysis]
362 Mieli-Vergani G, Vergani D, Czaja AJ, Manns MP, Krawitt EL, Vierling JM, Lohse AW, Montano-Loza AJ. Autoimmune hepatitis. Nat Rev Dis Primers. 2018;4:18017. [PMID: 29644994 DOI: 10.1038/nrdp.2018.17] [Cited by in Crossref: 92] [Cited by in F6Publishing: 83] [Article Influence: 23.0] [Reference Citation Analysis]
363 Pecoraro A, Crescenzi L, Varricchi G, Marone G, Spadaro G. Heterogeneity of Liver Disease in Common Variable Immunodeficiency Disorders. Front Immunol 2020;11:338. [PMID: 32184784 DOI: 10.3389/fimmu.2020.00338] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
364 Harrison L, Gleeson D. Stopping immunosuppressive treatment in autoimmune hepatitis (AIH): Is it justified (and in whom and when)? Liver Int 2019;39:610-20. [DOI: 10.1111/liv.14051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
365 Faulkes RE, Chauhan A, Knox E, Johnston T, Thompson F, Ferguson J. Review article: chronic liver disease and pregnancy. Aliment Pharmacol Ther 2020;52:420-9. [PMID: 32598048 DOI: 10.1111/apt.15908] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
366 Liberal R, de Boer YS, Andrade RJ, Bouma G, Dalekos GN, Floreani A, Gleeson D, Hirschfield GM, Invernizzi P, Lenzi M, Lohse AW, Macedo G, Milkiewicz P, Terziroli B, van Hoek B, Vierling JM, Heneghan MA; International Autoimmune Hepatitis Group (IAIHG). Expert clinical management of autoimmune hepatitis in the real world. Aliment Pharmacol Ther. 2017;45:723-732. [PMID: 28004405 DOI: 10.1111/apt.13907] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
367 Noguchi F, Chu PS, Yoshida A, Taniki N, Morikawa R, Hasegawa Y, Yamataka K, Hoshi H, Kasuga R, Tabuchi T, Ebinuma H, Shinoda M, Obara H, Kitagawa Y, Kanai T, Nakamoto N. Early Dynamics of MELD Scores Predict Corticosteroid Responsiveness to Severe Acute-Onset Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00609-1. [PMID: 34102339 DOI: 10.1016/j.cgh.2021.06.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
368 Fan X, Men R, Shen M, Yang L. Letter: elderly AIH patients-an important subgroup. Aliment Pharmacol Ther 2019;50:614. [PMID: 31414540 DOI: 10.1111/apt.15407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
369 Raquel Benedita Terrabuio D, Augusto Diniz M, Teofilo de Moraes Falcão L, Luiza Vilar Guedes A, Akeme Nakano L, Silva Evangelista A, Roberto Lima F, Pires Abrantes-Lemos C, José Carrilho F, Luiz Rachid Cancado E. Chloroquine Is Effective for Maintenance of Remission in Autoimmune Hepatitis: Controlled, Double-Blind, Randomized Trial. Hepatol Commun 2019;3:116-28. [PMID: 30619999 DOI: 10.1002/hep4.1275] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
370 Arvaniti P, Zachou K, Koukoulis GK, Dalekos GN. Postinfantile Giant Cell Hepatitis with Features of Acute Severe Autoimmune Hepatitis Probably Triggered by Diclofenac in a Patient with Primary Myelofibrosis. Case Reports Hepatol 2018;2018:9793868. [PMID: 29713554 DOI: 10.1155/2018/9793868] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
371 Takahashi A, Arinaga-Hino T, Ohira H, Abe K, Torimura T, Zeniya M, Abe M, Yoshizawa K, Takaki A, Suzuki Y, Kang JH, Nakamoto N, Fujisawa T, Tanaka A, Takikawa H; Japan AIH Study Group (JAIHSG). Non-alcoholic fatty liver disease in patients with autoimmune hepatitis. JGH Open 2018;2:54-8. [PMID: 30483564 DOI: 10.1002/jgh3.12046] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
372 Terziroli Beretta-Piccoli B, Mieli-Vergani G, Bertoli R, Mazzucchelli L, Nofziger C, Paulmichl M, Vergani D. Atovaquone/proguanil-induced autoimmune-like hepatitis. Hepatol Commun 2017;1:293-8. [PMID: 29404460 DOI: 10.1002/hep4.1039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
373 Aarslev K, Dige A, Greisen SR, Kreutzfeldt M, Jessen N, Vilstrup H, Deleuran B, Grønbæk H. Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis. Scandinavian Journal of Gastroenterology 2017;52:93-9. [DOI: 10.1080/00365521.2016.1233576] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
374 Behairy BE, El-Said HH, Konswa HA, El-Deen AEN, Adawy NM, Sira AM. Predictors of azathioprine toxicity in children with autoimmune hepatitis. Clin Exp Hepatol 2021;7:47-54. [PMID: 34027115 DOI: 10.5114/ceh.2021.104634] [Reference Citation Analysis]
375 Shi Y, Wang Q, Rong J, Ren J, Song X, Fan X, Shen M, Xia Y, Wang N, Liu Z, Hu Q, Ye T, Yu L. Synthesis and biological evaluation of (1,2,4)triazole[4,3-a]pyridine derivatives as potential therapeutic agents for concanavalin A-induced hepatitis. Eur J Med Chem 2019;179:182-95. [PMID: 31254920 DOI: 10.1016/j.ejmech.2019.06.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
376 Jing J, Wang RL, Zhao XY, Zhu Y, Niu M, Wang LF, Song XA, He TT, Sun YQ, Xu WT, Yu SM, Wang LP, Guo YM, Bai ZF, Xiao XH, Wang JB. Association between the concurrence of pre-existing chronic liver disease and worse prognosis in patients with an herb- Polygonum multiflorum thunb. induced liver injury: a case-control study from a specialised liver disease center in China. BMJ Open. 2019;9:e023567. [PMID: 30782709 DOI: 10.1136/bmjopen-2018-023567] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
377 Muratori P, Granito A, Lenzi M, Muratori L. Limitation of the simplified scoring system for the diagnosis of autoimmune Hepatitis with acute onset. Liver Int 2021;41:529-34. [PMID: 33389800 DOI: 10.1111/liv.14778] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
378 van den Brand FF, van Nieuwkerk CMJ, Verwer BJ, de Boer YS, de Boer NKH, Mulder CJJ, Bloemena E, Bakker CM, Vrolijk JM, Drenth JPH, Tan ACITL, Ter Borg F, Ter Borg MJ, van den Hazel SJ, Inderson A, Tushuizen ME, Bouma G. Biochemical efficacy of tioguanine in autoimmune hepatitis: a retrospective review of practice in the Netherlands. Aliment Pharmacol Ther 2018;48:761-7. [PMID: 30109891 DOI: 10.1111/apt.14939] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
379 Olivas I, Cobreros M, Londoño MC, Díaz-González Á. Budesonide In The First Line Treatment Of Patients With Autoimmune Hepatitis. Gastroenterol Hepatol 2021:S0210-5705(21)00319-8. [PMID: 34923033 DOI: 10.1016/j.gastrohep.2021.11.012] [Reference Citation Analysis]
380 Yodoshi T, Orkin S, Arce-Clachar AC, Bramlage K, Xanthakos SA, Mouzaki M, Valentino PL. Significance of autoantibody seropositivity in children with obesity and non-alcoholic fatty liver disease. Pediatr Obes 2021;16:e12696. [PMID: 32638543 DOI: 10.1111/ijpo.12696] [Reference Citation Analysis]
381 Xia D, Chen D, Cai T, Zhu L, Lin Y, Yu S, Zhu K, Wang X, Xu L, Chen Y. Nimbolide attenuated the inflammation in the liver of autoimmune hepatitis's mice through regulation of HDAC3. Toxicol Appl Pharmacol 2021;434:115795. [PMID: 34780724 DOI: 10.1016/j.taap.2021.115795] [Reference Citation Analysis]
382 Li Y, Yan L, Wang R, Wang Q, You Z, Li B, Zhang J, Huang B, Chen Y, Li Y, Lian M, Tang R, Qiu D, Gershwin ME, Xiao X, Miao Q, Ma X. Serum Immunoglobulin G Levels Predict Biochemical and Histological Remission of Autoimmune Hepatitis Type 1: A Single-Center Experience and Literature Review. Clin Rev Allergy Immunol 2021. [PMID: 33512642 DOI: 10.1007/s12016-021-08833-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
383 Takeuchi Y, Noritake H, Matsumoto M, Umemura M, Yamashita M, Kitsugi K, Takatori S, Ohta K, Ito J, Shimoyama S, Kaysuya A, Maruyama C, Fukuchi K, Dohtan S, Sakata H, Kawata K. Azathioprine-induced severe myelosuppression accompanied by massive hair loss and painful oral ulcer in an autoimmune hepatitis patient with NUDT15 minor variant: A case report. Clin Case Rep 2021;9:e04696. [PMID: 34466252 DOI: 10.1002/ccr3.4696] [Reference Citation Analysis]
384 Tansel A, Katz LH, El-Serag HB, Thrift AP, Parepally M, Shakhatreh MH, Kanwal F. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 1207-1217. e4. [PMID: 28215616 DOI: 10.1016/j.cgh.2017.02.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
385 McKiernan PJ. Multiparametric Magnetic Resonance Imaging to Monitor Pediatric Liver Disease: Looks Interesting but More Work to Do. J Pediatr Gastroenterol Nutr 2021;72:3-4. [PMID: 32960826 DOI: 10.1097/MPG.0000000000002949] [Reference Citation Analysis]
386 Losurdo G, Gravina AG, Maroni L, Gabrieletto EM, Ianiro G, Ferrarese A; Young Investigator group of SIGE, the Italian Society of Gastroenterology. Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Dig Liver Dis 2021:S1590-8658(21)00455-2. [PMID: 34509394 DOI: 10.1016/j.dld.2021.08.008] [Reference Citation Analysis]
387 Gatselis NK, Azariadis K, Lyberopoulou A, Dalekos GN. Programmed cell death-1 rs11568821 and interleukin-28B rs12979860 polymorphisms in autoimmune hepatitis. J Transl Autoimmun 2021;4:100126. [PMID: 34632357 DOI: 10.1016/j.jtauto.2021.100126] [Reference Citation Analysis]
388 Kunzmann LK, Schoknecht T, Poch T, Henze L, Stein S, Kriz M, Grewe I, Preti M, Hartl J, Pannicke N, Peiseler M, Sebode M, Zenouzi R, Horvatits T, Böttcher M, Petersen BS, Weiler-Normann C, Hess LU, Ahrenstorf AE, Lunemann S, Martrus G, Fischer L, Li J, Carambia A, Kluwe J, Huber S, Lohse AW, Franke A, Herkel J, Schramm C, Schwinge D. Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC). Hepatology 2020;72:1310-26. [PMID: 33090557 DOI: 10.1002/hep.31140] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
389 Ozaslan E, Efe C. Further considerations in autoimmune hepatitis. Journal of Hepatology 2016;64:1457-8. [DOI: 10.1016/j.jhep.2015.12.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
390 Stremmel W, Longerich T, Liere R, Vacata V, van Helden J, Weiskirchen R. Wilson disease — the impact of hyperimmunity on disease activity: A case report. World J Clin Cases 2021; 9(6): 1386-1393 [PMID: 33644206 DOI: 10.12998/wjcc.v9.i6.1386] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
391 Liberal R, de Boer YS, Heneghan MA. Established and novel therapeutic options for autoimmune hepatitis. The Lancet Gastroenterology & Hepatology 2021;6:315-26. [DOI: 10.1016/s2468-1253(20)30328-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
392 Wang Q, Yang F, Miao Q, Krawitt EL, Gershwin ME, Ma X. The clinical phenotypes of autoimmune hepatitis: A comprehensive review. J Autoimmun. 2016;66:98-107. [PMID: 26614611 DOI: 10.1016/j.jaut.2015.10.006] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 7.9] [Reference Citation Analysis]
393 Weber S, Benesic A, Rotter I, Gerbes AL. Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis. Liver Int 2019;39:1906-17. [PMID: 31319011 DOI: 10.1111/liv.14195] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
394 Nakamura T, Shirouzu T. Antibody-Mediated Rejection and Recurrent Primary Disease: Two Main Obstacles in Abdominal Kidney, Liver, and Pancreas Transplants. J Clin Med 2021;10:5417. [PMID: 34830699 DOI: 10.3390/jcm10225417] [Reference Citation Analysis]
395 Galaski J, Koop AC, Lütgehetmann M, Lohse AW, Weiler-Normann C. Autoantibodies to intracellular "rods and rings" structures in two patients with autoimmune hepatitis treated with azathioprine. Autoimmunity 2020;53:362-5. [PMID: 32662301 DOI: 10.1080/08916934.2020.1793135] [Reference Citation Analysis]
396 Candels LS, Rahim MN, Shah S, Heneghan MA. Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates. J Hepatol 2021;75:324-32. [PMID: 33872691 DOI: 10.1016/j.jhep.2021.03.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
397 Fu H, Li Y, Bai G, Yin R, Yin C, Shi W, Zhang L, Li R, Zhao R. Persistent cholestasis resulting from duodenal papillary carcinoma in an adolescent male: A case report. Medicine (Baltimore) 2019;98:e15708. [PMID: 31145285 DOI: 10.1097/MD.0000000000015708] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
398 Ma X, Qiu K. Chinese consensus on the diagnosis and management of autoimmune hepatitis (2015): Chinese Society of Hepatology, Chinese Society of Gastroenterology & amp; Chinese Society of Infectious Diseases. J Dig Dis. 2017; Apr 27. [Epub ahead of print]. [PMID: 28449401 DOI: 10.1111/1751-2980.12479] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
399 Sostre V, Patel HG, Mohamed A, Volfson A. A Case of Acute Autoimmune Hepatitis Superimposed on Chronic Hepatitis B Infection. Case Rep Gastrointest Med 2018;2018:2139607. [PMID: 29805819 DOI: 10.1155/2018/2139607] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
400 Czaja AJ. Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis. Aliment Pharmacol Ther 2020;51:1286-304. [PMID: 32363674 DOI: 10.1111/apt.15743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
401 Abe K, Fujita M, Hayashi M, Takahashi A, Ohira H. Association of serum 25-hydroxyvitamin D levels with severe necroinflammatory activity and inflammatory cytokine production in type I autoimmune hepatitis. PLoS One 2020;15:e0239481. [PMID: 33151930 DOI: 10.1371/journal.pone.0239481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
402 Abdollahi M, Khalilian Ekrami N, Ghojazadeh M, Boezen HM, Somi M, Alizadeh BZ. Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations? World J Gastroenterol 2020; 26(38): 5896-5910 [PMID: 33132643 DOI: 10.3748/wjg.v26.i38.5896] [Reference Citation Analysis]
403 Gonzalez RS, Washington K. Primary Biliary Cholangitis and Autoimmune Hepatitis. Surg Pathol Clin 2018;11:329-49. [PMID: 29751878 DOI: 10.1016/j.path.2018.02.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
404 Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel) 2021;13:1023. [PMID: 33804480 DOI: 10.3390/cancers13051023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
405 Weiler-normann C, Lohse AW. Nonalcoholic Fatty Liver Disease in Patients with Autoimmune Hepatitis: Further Reason for Teeth GNASHing? Dig Dis Sci 2016;61:2462-4. [DOI: 10.1007/s10620-016-4258-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
406 Wohlfahrt T, Rauber S, Uebe S, Luber M, Soare A, Ekici A, Weber S, Matei AE, Chen CW, Maier C, Karouzakis E, Kiener HP, Pachera E, Dees C, Beyer C, Daniel C, Gelse K, Kremer AE, Naschberger E, Stürzl M, Butter F, Sticherling M, Finotto S, Kreuter A, Kaplan MH, Jüngel A, Gay S, Nutt SL, Boykin DW, Poon GMK, Distler O, Schett G, Distler JHW, Ramming A. PU.1 controls fibroblast polarization and tissue fibrosis. Nature 2019;566:344-9. [PMID: 30700907 DOI: 10.1038/s41586-019-0896-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 17.3] [Reference Citation Analysis]
407 Konstantakis C, Tselekouni P, Kalafateli M, Triantos C. Vitamin D deficiency in patients with liver cirrhosis. Ann Gastroenterol. 2016;29:297-306. [PMID: 27366029 DOI: 10.20524/aog.2016.0037] [Cited by in Crossref: 19] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
408 Chapman RW, Aspinall RJ, Trivedi P, Wright G, Heneghan M. Challenges in the use of corticosteroids in the management of autoimmune hepatitis. Br J Hosp Med (Lond) 2019;80:594-9. [PMID: 31589514 DOI: 10.12968/hmed.2019.80.10.594] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
409 Shahini E, Iannone A, Romagno D, Armandi A, Carparelli S, Principi M, Viggiani MT, Ierardi E, Di Leo A, Barone M. Clinical relevance of serum non-organ-specific antibodies in patients with HCV infection receiving direct-acting antiviral therapy. Aliment Pharmacol Ther. 2018;48:1138-1145. [PMID: 30375693 DOI: 10.1111/apt.14999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
410 Pape S, Gevers TJG, Vrolijk JM, van Hoek B, Bouma G, van Nieuwkerk CMJ, Taubert R, Jaeckel E, Manns MP, Papp M, Sipeki N, Stickel F, Efe C, Ozaslan E, Purnak T, Nevens F, Kessener DJN, Kahraman A, Wedemeyer H, Hartl J, Schramm C, Lohse AW, Heneghan MA, Drenth JPH. High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. Liver Int 2020;40:2164-71. [PMID: 32410363 DOI: 10.1111/liv.14513] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
411 Janmohamed A, Hirschfield GM. Editorial: autoimmune hepatitis - identifying options for treatment. Aliment Pharmacol Ther 2016;43:1236-7. [DOI: 10.1111/apt.13607] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
412 Liwinski T, Schramm C. Autoimmune hepatitis — update on clinical management in 2017. Clinics and Research in Hepatology and Gastroenterology 2017;41:617-25. [DOI: 10.1016/j.clinre.2017.07.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
413 Bianco C, Coluccio E, Prati D, Valenti L. Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders. J Clin Med 2021;10:423. [PMID: 33499290 DOI: 10.3390/jcm10030423] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
414 Dokmak A, Trivedi HD, Bonder A, Wolf J. Pregnancy in Chronic Liver Disease: Before and After Transplantation. Ann Hepatol 2021;:100557. [PMID: 34656772 DOI: 10.1016/j.aohep.2021.100557] [Reference Citation Analysis]
415 Vierling JM, Kerkar N, Czaja AJ, Mack CL, Adams D, Assis DN, Manns MP, Mayo MJ, Nayfeh T, Majzoub AMM, Alzuabi MA, Ding J, Haffar S, Murad MH, Alsawas M. Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta‐Analyses Supporting American Association for the Study of Liver Diseases Guidelines. Hepatology 2020;72:753-69. [DOI: 10.1002/hep.31407] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
416 Yu ZJ, Zhang LL, Huang TT, Zhu JS, He ZB. Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis. Eur J Gastroenterol Hepatol 2019;31:873-7. [PMID: 31150366 DOI: 10.1097/MEG.0000000000001367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
417 Günther C, He GW, Kremer AE, Murphy JM, Petrie EJ, Amann K, Vandenabeele P, Linkermann A, Poremba C, Schleicher U, Dewitz C, Krautwald S, Neurath MF, Becker C, Wirtz S. The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis. J Clin Invest 2016;126:4346-60. [PMID: 27756058 DOI: 10.1172/JCI87545] [Cited by in Crossref: 84] [Cited by in F6Publishing: 55] [Article Influence: 14.0] [Reference Citation Analysis]
418 Tang HH, Li HL, Li YX, You Y, Guan YY, Zhang SL, Liu LX, Bao WL, Zhou Y, Shen XY. Protective effects of a traditional Chinese herbal formula Jiang-Xian HuGan on Concanavalin A-induced mouse hepatitis via NF-κB and Nrf2 signaling pathways. J Ethnopharmacol 2018;217:118-25. [PMID: 29421593 DOI: 10.1016/j.jep.2018.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
419 Vitale G, Gitto S, Campani C, Turco L, Baldan A, Marra F, Morelli MC. Biological therapies in patients with liver disease: are they really lifesavers? Expert Opin Biol Ther 2021;:1-18. [PMID: 34860629 DOI: 10.1080/14712598.2022.2013799] [Reference Citation Analysis]
420 Gustot T. JHEP Reports: The fourth issue. JHEP Rep 2019;1:257-8. [PMID: 32039375 DOI: 10.1016/j.jhepr.2019.09.004] [Reference Citation Analysis]
421 Fischer HP, Goltz D. [Autoimmune liver diseases]. Pathologe 2020;41:444-56. [PMID: 32749523 DOI: 10.1007/s00292-020-00807-7] [Reference Citation Analysis]
422 Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, van der Meer AJ, Feld JJ, Gulamhusein A, Lammers WJ, Ponsioen CY, Carbone M, Mason AL, Mayo MJ, Invernizzi P, Battezzati PM, Floreani A, Lleo A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Thorburn D, Trivedi PJ, Verhelst X, Parés A, Janssen HLA, Hansen BE; GLOBAL PBC Study Group. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. Am J Gastroenterol 2020;115:1066-74. [PMID: 32618657 DOI: 10.14309/ajg.0000000000000557] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
423 Gaspar R, Andrade P, Silva M, Peixoto A, Lopes J, Carneiro F, Liberal R, Macedo G. Hepatic granulomas: a 17-year single tertiary centre experience. Histopathology 2018;73:240-6. [PMID: 29603759 DOI: 10.1111/his.13521] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
424 Komori A. Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol 2021;27:58-69. [PMID: 33291862 DOI: 10.3350/cmh.2020.0189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
425 Zachou K, Arvaniti P, Azariadis K, Lygoura V, Gatselis NK, Lyberopoulou A, Koukoulis GK, Dalekos GN. Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis. Hepatol Res 2019;49:96-104. [PMID: 30248210 DOI: 10.1111/hepr.13252] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
426 Pape S, Nevens F, Verslype C, Mertens C, Drenth JPH, Tjwa ETTL. Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience. Eur J Gastroenterol Hepatol. 2020;32:727-732. [PMID: 31658173 DOI: 10.1097/meg.0000000000001580] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
427 Chang A, Charoenlap C, Akarapatima K, Rattanasupar A, Prachayakul V. Immunoglobulin G4-associated autoimmune hepatitis with peripheral blood eosinophilia: a case report. BMC Gastroenterol 2020;20:420. [PMID: 33308169 DOI: 10.1186/s12876-020-01559-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
428 Janowski K, Shumbayawonda E, Dennis A, Kelly M, Bachtiar V, DeBrota D, Langford C, Thomaides-Brears H, Pronicki M, Grajkowska W, Wozniak M, Pawliszak P, Chełstowska S, Jurkiewicz E, Banerjee R, Socha P. Multiparametric MRI as a Noninvasive Monitoring Tool for Children With Autoimmune Hepatitis. J Pediatr Gastroenterol Nutr 2021;72:108-14. [PMID: 32925554 DOI: 10.1097/MPG.0000000000002930] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
429 Purnak T, Efe C, Kav T, Wahlin S, Ozaslan E. Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis. Dig Dis Sci. 2017;62:2900-2907. [PMID: 28871464 DOI: 10.1007/s10620-017-4728-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
430 Rutter K, Horvatits T, Drolz A, Roedl K, Siedler S, Kluge S, Fuhrmann V. [Acute liver failure]. Med Klin Intensivmed Notfmed 2018;113:174-83. [PMID: 27241777 DOI: 10.1007/s00063-016-0156-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
431 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 2021;56:593-619. [PMID: 34231046 DOI: 10.1007/s00535-021-01788-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]